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IMPACT OF DIFFERENTIATION STATUS OF KIDNEY PROGENITORS IN WILMS 
TUMOR DEVELOPMENT 
  
Le Huang, M.S. 
 
Advisory Professor: Vicki Huff, Ph.D. 
 
 
 
Wilms tumor is one of the most common solid tumors in children. It is an embryonic 
cancer of the kidney and is thought to arise from undifferentiated renal mesenchyme. 
However, the differentiation status of cells in the mesenchyme that can give rise to Wilms 
tumors is unknown. Gene expression analysis of a large panel of Wilms tumor patients has 
identified different subsets of Wilms tumors that are distinct in their clinical outcomes and 
gene expression signatures. These subsets express specific genes that correspond to 
different stages of differentiation during renal development, suggesting that Wilms tumors 
may arise from transformed cells at different states of differentiation. Wilms tumors are 
genetically heterogeneous, which can also affect the tumor biology and pathology. To test 
whether cells at different states of differentiation were tumorigenic, we used progenitor cell-
type-specific Cre to introduce mutations of Wilms Tumor gene 1 (Wt1) or β-catenin into fetal 
kidney cells in a progenitor-specific manner. We found that the nephron progenitors but not 
the stroma progenitors were able to give rise to Wilms tumors and that the different types of 
mutations introduced into nephron progenitor cells resulted in Wilms tumors with differing 
histology and expression of developmentally regulated genes. Also, to investigate the 
mechanisms by which WT1 mutations cause a predisposition to Wilms tumors, we studied 
the in vivo effects of Wt1 ablation in different renal progenitor cells. We found that Wt1 
ablation in stroma progenitors did not affect nephrogenesis but that Wt1 is required for 
nephron progenitors to undergo mesenchyme to epithelia transition. 
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Chapter 1: Introduction 
1.1 Wilms tumors (WT) 
Wilms tumor, also named nephroblastoma, is one of the most common solid tumors in 
children. It is a pediatric cancer of kidney and affects 1 in every 10,000 live births in North 
America (Beckwith, 1983). It was first recognized by the German surgeon Max Wilms in 
1899 in a 3-year-old patient. The average age of tumor onset for Wilms tumor is 38 months 
old in the U.S., and the typical symptoms are growth of an abdominal mass and pain 
(Breslow et al., 1993). The tumors are often in one kidney, with less than 5% occurring in 
both kidneys (Breslow et al., 1993). Wilms tumors rarely metastasize but if they do, they 
metastasize mainly to the lungs, lymph nodes, bones and brain (NLM, 2015). Wilms tumor 
patients are usually treated with a combination of surgery and chemotherapy, and if the 
tumor is at an advanced stage, radiation therapy is also applied. The 5-year survival rate is 
approximately 90% (Smith et al., 2014). Despite the fact that 90% Wilms tumors are curable, 
those who survive their tumors suffer from side effects of chemotherapy and radiation 
therapy. Understanding the etiology of Wilms tumor will help in the development of improved 
treatment with fewer side effects.  
Wilms tumors are usually encapsulated within a fibrotic pseudocapsule, separated from 
the adjacent normal kidney. The precursor lesions of WT are known as nephrogenic rests 
(Beckwith, 1998). Nephrogenic rests are nodules of blastemal cells, which are mesenchymal 
cells arrested at an early stage of differentiation during kidney development (Beckwith, 
1998). Genetic studies of Wilms tumors have shown that the nephrogenic rests and Wilms 
tumors share the same mutations, however, additional mutations are found in Wilms tumors, 
suggesting a sequential progression from the nephrogenic rest to Wilms tumor (Fukuzawa et 
al., 2007). When second genetic mutations or oncogenic events occur within the 
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nephrogenic rests, the lesional cells may be transformed and clonal expansion of such cells 
can progress to the development of Wilms tumors.  
The typical histology of Wilms tumor is triphasic, consisting of undifferentiated blastemal 
elements as well as differentiating epithelial and stromal elements (Beckwith and Palmer, 
1978). Wilms tumors are heterogeneous, with varying degrees of each element. Abnormally 
differentiated elements such as myogenic, chondrogenic, osteogenic or adipogenic cells can 
also be found in some of the Wilms tumors. Histologically, Wilms tumors recapitulate the 
development of embryonic kidney (Fig. 1.1). The blastemal elements in the tumor appear 
like the undifferentiated metanephric mesenchyme of the developing kidney, whereas the 
epithelial elements resemble the differentiating epithelial structures after mesenchyme to 
epithelial transition, including comma-shaped body, S-shaped body, tubules and glomeruli 
(Beckwith, 1983). Although different histologic components are present in Wilms tumors, 
studies have shown that these components shared the same genetic changes, suggesting 
that Wilms tumor is a clonal expansion of the transformed undifferentiated mesenchymal cell 
that can potentially differentiate to epithelial, stromal or ectopic elements (Zhuang et al., 
1997) (Guertl et al., 2006). 
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Figure 1.1 Wilms tumor histologically recapitulates fetal kidney 
 
(A) Human fetal kidney. (B) Human Wilms tumor. B, S, and E designate 
blastemal, epithelial and stromal components, respectively. 
Images are from website http://www.humpath.com/spip.php?article5075 
A B 
S 
S 
E E B 
B 
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1.2 Kidney development 
To understand Wilms tumorigenesis, it is important to understand the process of kidney 
development (Fig. 1.2). Kidney development starts with the formation of the Wolffian duct 
and the nephrogenic cord from the intermediate mesenchyme (Davidson, 2008). The 
nephrogenic cord generates the pronephros, mesonephros and metanephros, with the first 
two degenerating during mammalian embryonic development. The Wolffian duct extends the 
ureteric buds to invade the metanephric mesenchyme, and at the same time, the 
metanephric mesenchyme signals to the ureteric buds and induces them to branch 
iteratively. In response, the ureteric buds stimulate the metanephric mesenchyme to 
differentiate. The metanephric mesenchyme first condenses around the tips of the ureteric 
buds to form the cap mesenchyme (CM). Then the CM undergoes mesenchyme to epithelial 
transition (MET) and forms the renal vesicles (RV) proximal to the ureteric buds. The 
resulting renal vesicles further epithelialize and connect to the ureteric buds to form the 
comma-shaped bodies and the S-shaped bodies. The S-shaped bodies are segmented and 
differentiate, together with the ureteric buds, to form the fully mature nephrons, the 
functional units of the kidney, which include the proximal tubules, distal tubules, loops of 
Henle and glomeruli (Davidson, 2008). 
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Figure 1.2 Diagram of kidney development 
 
(A) Metanephric kidney development starts with ureteric bud (UB) invasion into 
metanephric mesenchyme. (B & C) UB branches repeatedly and elongates the 
stalk. (D) Metanephric mesenchyme condenses around the UB tip. (E & F) 
The mesenchyme undergoes mesenchyme to epithelial transition and 
differentiates to form renal vesicle, comma-shaped body and S-shaped body. 
(G) The S-shaped body connects to the UB and further differentiates and 
segments to form the nephron. 
Image is from Review: Shah, M.M., Sampogna, R.V., Sakurai, H., Bush, K.T., and Nigam, S.K. (2004). Branching 
morphogenesis and kidney disease. Development 131, 1449-1462. 
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1.3 Kidney progenitor compartments 
During kidney development, there are two major types of progenitors in the 
undifferentiated metanephric mesenchyme: the stromal progenitor and the nephron 
progenitor (Fig. 1.3 A) (Mugford et al., 2009) (Self et al., 2006) (Kobayashi et al., 2014). The 
specification of the stromal progenitor and the nephron progenitor starts from the common 
Osr1-expressing precursor cells in intermediate mesenchyme and metanephric 
mesenchyme (MM) (Mugford et al., 2008b).  
The stromal progenitors are at the periphery of the metanephric mesenchyme and 
surround the nephron progenitors. They specifically express FOXD1 and give rise to the 
interstitium, pericytes, mesangial cells, and smooth muscle cells in the kidney (Humphreys 
et al., 2010; Kobayashi et al., 2014).  
The nephron progenitors reside in the cap mesenchyme (CM) that surrounds the tips of 
the ureteric buds (Fig. 1.3) (Self et al., 2006). One proposal is that the CM contains 
heterogeneous cell populations due to the different expression pattern of transcription 
factors and its spatial location surrounded by different growth factors, ligands and cell types 
(Hendry et al., 2011). As defined by gene expression pattern, the CM contains two 
subpopulations, the uninduced and the induced CM (Mugford et al., 2009). Cells within the 
uninduced CM express both markers CITED1 and SIX2. The CITED1+ SIX2+ cells have 
been shown to be the self-renewing population, and they resist the differentiation-inducing 
signals from ureteric buds (Brown et al., 2013). However, the induced CM expresses SIX2 
but not CITED1 (CITED1- SIX2+) and starts to differentiate and undergo MET to form RVs 
(Brown et al., 2013; Mugford et al., 2009). The nephron progenitors (SIX2+ or CITED1+) give 
rise to the majority of the cells in the nephrons, including epithelial cells in the glomeruli, 
proximal tubules, distal tubules and loop of Henle (Kobayashi et al., 2008). In situ 
hybridization of whole mount embryonic kidneys with transcription factors identified 
differences in the gene expression patterns between the uninduced CM and the induced CM 
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(Mugford et al., 2009). The uninduced CITED1+ SIX2+ cells express genes Meox1 and Dpf3, 
while the induced CITED1- SIX2+ cells express genes Wnt4, Fgf8, Pax8, Lhx1 and Pea3, 
suggesting different transcription programs between the uninduced and induced CM cells 
(Mugford et al., 2009).  
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Ureteric 
bud 
Foxd1+: stromal progenitor 
Six2+: CM 
Cited1+: uninduced CM 
Figure 1.3 Diagram of kidney progenitor compartments in mesenchyme and 
interactions of proteins between CM, UB and stromal. 
 
(A) The Foxd1+ stromal progenitors are located outside the CM and produce 
interstitium, pericyte and mesangial cells etc. The uninduced CM expresses 
both Cited1 and Six2, while the induced CM is Cited1- Six2+. The nephron 
progenitors in the CM give rise to the majority of the cells in the nephron.  
(B) Diagram of the key genes in each compartment in the nephrogenic zone and 
the interactions between the compartments of CM, UB and stromal 
mesenchyme. 
Image B is from Review: Little, M., Georgas, K., Pennisi, D., and Wilkinson, L. (2010). Kidney development: two tales of 
tubulogenesis. Current topics in developmental biology 90, 193-229. Figure used with permission. 
A B 
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1.4 Functions of progenitor markers FOXD1, SIX2 and CITED1 in renal progenitors 
Expression of FOXD1, SIX2 and CITED1 demarcates stromal or nephron progenitors, 
respectively. It is important to understand the roles of each marker in renal progenitors 
during kidney development. 
Foxd1, a transcription factor, is expressed in the cortical stromal mesenchyme (Hatini et 
al., 1996). FOXD1 expressing cells have been shown to be the multipotent self-renewing 
stromal progenitors in mouse kidneys (Kobayashi et al., 2014). Foxd1 knockout mice died 
immediately after birth with a phenotype of renal agenesis, demonstrating an essential role 
of the FOXD1+ stromal mesenchyme in nephrogenesis (Hatini et al., 1996). Through 
paracrine signaling, Foxd1 regulates the epithelial differentiation of the nephron 
mesenchyme and the growth and branching of the ureteric bud (Zhang et al., 2003).  
In the CM, Six2, a homeobox transcription factor, is required for the maintenance of self-
renewal and multipotency of the nephron progenitor in an autonomous manner (Kobayashi 
et al., 2008). SIX2 is expressed in both uninduced CM and induced CM, but the expression 
of SIX2 decreases in the RV (Mugford et al., 2009). Six2 deletion mice died shortly after 
birth and showed renal hypogenesis (Self et al., 2006). Six2 deletion caused the depletion of 
the nephron progenitors and the ectopic differentiation of the nephron progenitors to 
epithelial cells (Self et al., 2006). Six2 activates its own expression autonomously (Brodbeck 
et al., 2004). To maintain the nephron progenitor, SIX2 is required for the expression of 
OSR1, which interacts with SIX2 through the TCF/LEF complex (Xu et al., 2014a). SIX2 and 
β-CATENIN compete to interact with the TCF/LEF complex in the nephron progenitors. 
However, SIX2 maintains the self-renewal capacity, whereas β-CATENIN promotes 
differentiation (Park et al., 2012).  
CITED1, Cbp/p300-interacting transactivator with Glu/Asp-rich C-terminal domain 1, is a 
non-DNA binding transcpitional regulator. CITED1 is exclusively expressed in the nephron 
progenitor in the uninduced CM, and its expression decreases as the progenitor starts to 
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differentiate (Boyle et al., 2008). However, Cited1 deletion does not affect kidney 
development, suggesting that it is not required for nephrogenesis (Boyle et al., 2007).  
 
1.5 Signaling and interactions between kidney progenitor compartments 
There are networks of intensive signaling and crosstalk between stromal progenitors, 
nephron progenitors and ureteric buds to orchestrate the complex molecular interactions 
and morphogenesis in kidneys (Fig. 1.3 B). 
The metanephric mesenchyme expresses and secretes the growth factor GDNF which 
then binds to the GDNF receptor C-RET expressed in the cells of the ureteric buds (Patel 
and Dressler, 2013; Schuchardt et al., 1994). GDNF expression in the MM is controlled by 
transcription factors Eya1, Pax2, and Six1 and Six2 (Reidy and Rosenblum, 2009). The 
GDNF-C-RET signaling induces the outgrowth and branching of the ureteric bud through the 
PI-3K/AKT and ERK pathways (Tang et al., 2002). GDNF-C-RET signaling also increases 
the cell migration ability of ureteric buds to promote ureteric bud invasion into the 
metanephric mesenchyme (Tang et al., 1998). 
Reciprocally, the ureteric bud sends signals to the nephron progenitors to regulate cell 
survival, proliferation and differentiation (Mori et al., 2003). To maintain nephron progenitor 
survival, FGF signaling is critical. Specifically, FGF9 secreted from the ureteric buds and 
FGF20 expressed in the CM are necessary and sufficient for nephron progenitors to 
proliferate, survive and maintain stemness (Barak et al., 2012). WNT9B derived from the 
ureteric buds is also required for the self-renewal and proliferation of nephron progenitors 
via canonical β-CATENIN signaling (Karner et al., 2011). Also, WNT9B/β-CATENIN induces 
early differentiation the CITED1+ nephron progenitors (Carroll et al., 2005). SIX2 and 
WNT9B/β-CATENIN coordinate the balance between the maintenance of stemness and 
differentiation (Karner et al., 2011). In the presence of WNT9B/β-CATENIN signaling, 
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nephron progenitors with high levels of SIX2 favor maintenance of self-renewal and 
proliferation, whereas progenitors with low expression of SIX2 are stimulated to differentiate 
by WNT9B/β-CATENIN (Karner et al., 2011). WNT9B activates WNT4 in differentiating cells 
to form renal vesicles (Carroll et al., 2005). Although activation of β-CATENIN induces 
differentiation, levels of this protein must be reduced and fine-tuned in order for cells to 
further differentiate and epithelialize (Park et al., 2007). Moreover, in vivo genetic studies 
have shown that Notch signaling can substitute for WNT signaling and induce the 
mesenchyme to epithelia transition of nephron progenitor (Boyle et al., 2011).  
Stromal mesenchyme is also critical in regulating functions of nephron progenitors. The 
stromal progenitor is required for renal morphogenesis (Hum et al., 2014). Deletion of 
Foxd1, a marker for stromal progenitors, leads to failed differentiation of the nephron 
progenitors through DCN (Small leucine rich proteoglycan decorin)–BMP/SMAD signaling 
from stromal progenitors (Fetting et al., 2014).  BMP-SMAD signaling primes the 
CITED1+SIX2+ uninduced nephron progenitors to be susceptible to induction of 
differentiation (Brown et al., 2013). FAT-HIPPO signaling from stromal mesenchyme 
cooperates with WNT9B to control the differentiation of nephron progenitors (Das et al., 
2013).  
Both the stromal mesenchyme and the ureteric buds send signals to nephron 
progenitors and coordinate the control of nephron progenitor maintenance and 
differentiation. However, not much is known about whether the stromal progenitors are 
regulated by the nephron progenitors or the ureteric buds and how they are regulated.  
 
1.6 Pre-MM: Induction of metanephric mesenchyme 
The metanephric mesenchyme (MM) is derived from the intermediate mesenchyme. 
There are many key transcription factors that interact to generate and define the MM. These 
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transcription factors, such as Osr1, Eya1, Hox11, Six1 and Pax2, are expressed in the 
intermediate mesoderm and the MM, and are critical for the specification of the MM. Genetic 
studies have shown that loss of function of these transcription factors causes hypoplasia or 
kidney agenesis (Patel and Dressler, 2013). 
OSR1 is expressed in the intermediate mesenchyme cells from which both metanephric 
stromal progenitors and nephron progenitors arise (Mugford et al., 2008b).  OSR1 is 
required for the induction of metanephric mesenchyme from the intermediate mesenchyme 
(Wang et al., 2005). In the metanephric mesenchyme, OSR1 expression is restricted to the 
CM (SIX2+) and it works synergistically with SIX2 to maintain nephron progenitors (Mugford 
et al., 2008b) (Xu et al., 2014a). 
EYA1 is also expressed in the intermediate mesenchyme. EYA1+ cells in the 
intermediate mesenchyme give rise to the nephron forming cells. Deletion of Eya1 results in 
loss of SIX2 and premature epithelialization of the nephron progenitors, indicating that Eya1 
is important in regulating nephron progenitor self-renewal (Xu et al., 2014b). Eya1-/- mice do 
not have the outgrowth of the ureteric bud and the specification of the metanephric 
mesenchyme, which is likely mediated through SIX1 and PAX2 (Xu et al., 1999) (Sajithlal et 
al., 2005). 
Hox11 is a paralogous set of genes, Hoxa11, Hoxc11 and Hoxd11, with redundant 
functions in regulating kidney development. HOXD11 has been shown to activate SIX2 in 
the intermediate mesenchyme and commit the intermediate mesenchyme to the MM 
(Mugford et al., 2008a). The triple compound mutant Hoxa11-/-Hoxc11-/-Hoxd11-/- results in a 
failure in the induction of MM and the outgrowth of the ureteric bud (Wellik et al., 2002). 
HOX11 interacts with PAX2 and EYA1 and the formed HOX-PAX-EYA complex is essential 
to activate Six2 to maintain the nephron progenitor population (Gong et al., 2007).  
PAX2 is expressed in the mesenchymal and ductal components of the urogenital system 
(Torres et al., 1995). Pax2 and its related Pax gene family member, Pax8, are required and 
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sufficient for the specification of nephric lineage from the intermediate mesenchyme 
(Bouchard et al., 2002). Pax2 activates Wnt4 to induce the nephron progenitor to 
differentiate (Torban et al., 2006). Pax2 deletion mice resulted in failure to develop kidneys, 
ureters and genital tracts (Torres et al., 1995). 
 
1.7 Post-MM: Epithelial differentiation of nephron progenitor 
In the MM, after the induction of differentiation, the nephron progenitor undergoes MET 
and forms the renal vesicles, where as Wnt4, Pax8, Lef1, Lhx1 and Fgf8 are expressed to 
promote epithelial differentiation (Mugford et al., 2009) (Little and McMahon, 2012). The 
renal vesicle is comprised of primitive epithelium with a basement membrane and a lumen, 
located proximal to the ureteric bud (Patel and Dressler, 2013). During morphogenesis, the 
renal vesicle is followed by the formation of the comma-shaped body, S-shaped body, and 
fully differentiated nephron (Patel and Dressler, 2013). Gene expression analysis identified a 
restricted expression pattern of marker genes in the renal vesicle, which correlates to the 
specification of glomerular, proximal and distal segments (Little and McMahon, 2012). Along 
the proximal-distal patterning, CADHERINs are differentially expressed, reflecting the 
regionalization of segmentation (Little and McMahon, 2012). CADHERIN-6 is a marker for 
the proximal compartment in the comma-shaped body and S-shaped body (Cho et al., 
1998). E-CADHERIN is expressed in more maturely differentiated epithelium such as the 
proximal tubule and distal tubule (Shimazui et al., 2000). A study of the molecular 
mechanism of nephron patterning has shown Notch2 null mutants lack the formation of the 
proximal segments, suggesting that NOTCH signaling is required for nephron segmentation 
(Cheng et al., 2007). 
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1.8 Molecular profiling of Wilms tumors showed a similar profile to the early stage of 
kidney development 
Wilms tumor not only recapitulates the fetal kidney histologically, but it also molecularly 
mimics the gene expression pattern of fetal kidney. A comparison of gene expression 
analysis between Wilms tumors and fetal kidneys at early and late stage of development 
revealed that the gene expression profile of Wilms tumor was similar to that of the 
committed metanephric mesenchyme in the transition of mesenchyme to epithelia (Li et al., 
2002). The overexpressed genes shared by both Wilms tumor and the metanephric 
mesenchyme included Pax2, Eya1, HBF2, Hoxa11, Six1, Meox1 and Sall2, which play an 
important role on the survival, proliferation and function of the mesenchyme cells (Li et al., 
2002). Further analysis of transcription profile of specific cellular components in Wilms 
tumors, e.g. the blastemal, epithelial and stromal, demonstrated that all these components 
expressed genes that are highly expressed in metanephric mesenchyme at the earliest 
stage of renal development (Maschietto et al., 2008). Tumors also expressed genes 
expressed at a late stage of differentiation. However, tumor blastema had the least in 
common with the expression profile at a later stage of differentiation, while the tumor 
epithelial and stromal elements showed higher commonality with it (Maschietto et al., 2008). 
These molecular profiling results indicate that Wilms tumor arises from cells arrested at an 
early metanephric mesenchymal stage during kidney development. 
 
1.9 Wilms tumor genetics: WT1, β-CATENIN, WTX, and IGF2 
Mutations of a few genes have been identified in Wilms tumors, such as Wilms Tumor 
Gene 1 (WT1), β-CATENIN (CTNNB1), Wilms Tumor gene on the X chromosome (WTX) 
(Ruteshouser et al., 2008), IGF2 (Ogawa et al., 1993), DROSHA, DICER1 (Wu et al., 2013) 
and TP53  (Bardeesy et al., 1994; Huff, 2007).  
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WT1 is found mutated in 20% of tumors. The mutations included deletion, truncation or 
missense mutations, which resulted in the loss of functional WT1 (Ruteshouser et al., 2008). 
WT1 mutations are associated with mixed triphasic histology in Wilms tumors (Gadd et al., 
2012). WT1 is a transcription factor with four Kruppel type zinc finger domains and regulates 
the expression of genes involved in cell differentiation, survival and proliferation (Mrowka 
and Schedl, 2000). One of its isoforms also regulates mRNA processing (Hohenstein and 
Hastie, 2006). Wt1 knock-out mice lacked the development of kidneys and died at mid-
gestation due to defects in the development of cardiovasculature (Kreidberg et al., 1993). 
70% of Wilms tumors exhibited loss of imprinting of IGF2, resulting in biallelic expression 
of IGF2 (Steenman et al., 1994). The H19-Imprinting Control Region (ICR) region on the 
maternal allele transcriptionally represses the expression of IGF2 on the same allele. 
Normally IGF2 is expressed from the paternal allele but not the maternal one. However, 
deletion of H19-ICR region on the maternal allele results in biallelic Igf2 expression 
(Leighton et al., 1995). IGF2 is a fetal mitogen that promotes proliferation of mesenchymal 
cells in kidney development.  
β-CATENIN activation mutations occur in 15% of Wilms tumors and are frequently found 
associated with WT1 mutations (Maiti et al., 2000). Studies have found a sequential 
occurrence of genetic alterations during the progression from nephrogenic rest to tumor 
(Fukuzawa et al., 2007). In the same individual, the nephrogenic rests carried only WT1 
mutation, but the tumor had the same WT1 mutation and an additional β-catenin mutation 
(Fukuzawa et al., 2007). This result suggests that a WT1 mutation in nephrogenic rests is 
essential but not sufficient for cell transformation, and when a second mutation such as β-
CATENIN stabilization occurs, the nephrogenic rest becomes tumorigenic (Fukuzawa et al., 
2007).  
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WTX, a gene on the X chromosome, is found mutated in 20% of Wilms tumors 
(Ruteshouser et al., 2008). WTX has been shown to negatively regulate WNT/β-CATENIN 
signaling (Major et al., 2007). Mutant mice with germ-line knock-out of Wtx died after birth 
and had malformation in the mesenchyme derived tissues (Moisan et al., 2011). Wtx 
deletion in the mesenchyme progenitors resulted in changed fate of the lineage restricted 
cells and delayed differentiation due to increased WNT/β-CATENIN signaling (Moisan et al., 
2011). 
DICER1 syndrome patients who have germ-line DICER null mutations are predisposed 
to Wilms tumors. Very recently, genes involved in the micro RNA biogenesis pathway were 
found to be associated with 15% Wilms tumors (Torrezan et al., 2014). These genes include 
DROSHA (12%) (Torrezan et al., 2014), DICER1 (2.6%) (Wu et al., 2013) and some other 
micro RNA processing genes, suggesting a role of micro RNA biogenesis in Wilms tumor 
development (Torrezan et al., 2014). 
 
1.10 Wilms tumor mouse models 
Three different genetic mouse models of Wilms tumors have been generated so far. Our 
lab has generated the first one by ablating Wt1 somatically and mosaically in the 
background of bi-allelic Igf2 expression (Hu et al., 2010). In this model, a tamoxifen 
inducible Cre-ERTM was used to ablate Wt1 mosaically and somatically at E11.5, an early 
stage of kidney development (UbCre-Wt1-Igf2). The Wt1 was ablated by CRE in a non-
specific manner in kidney cells. This mouse model of Wilms tumor had typical triphasic 
histology, mimicking the triphasic histology of human Wilms tumors. Developmentally, Wt1 
ablation only blocked mesenchyme differentiation (Hu et al., 2010). The tumors with Wt1 
ablation and Igf2 upregulation had increased ERK signaling, corresponding to a subset of 
human WTs with elevated ERK1/2 phosphorylation (Hu et al., 2010). 
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A second genetic mouse model of Wilms tumor had stabilized β-CATENIN with or 
without the activation of K-RAS in kidney epithelial cells (Clark et al., 2011). This study 
applied a metanephric mesenchyme specific tamoxifen inducible Cre, Cited1CreERT2, and 
activated the CRE postnatally to stabilize β-CATENIN by deleting exon 3 of Ctnnb1. In 
addition to targeting the mesenchyme, they also used a proximal tubule specific Cre 
transgene γGT-Cre to activate β-catenin and K-Ras. With both methods, mutant mice 
developed primitive epithelial Wilms tumors. Moreover, the activation of both β-catenin and 
K-Ras synergistically caused metastasis of Wilms tumors to the lungs. Molecularly, the 
mouse primary Wilms tumors showed increased ERK and PI3K/AKT signaling (Clark et al., 
2011).  
Very recently, the overexpression of Lin28 with Wt1-Cre induction in the intermediate 
mesenchyme derivatives led to the development of Wilms tumors (Urbach et al., 2014). 
Lin28 is an RNA-binding protein and is important in the maintenance of stem cell 
proliferation and self-renewal (Urbach et al., 2014). The tumors with Lin28 overexpression 
displayed a phenotype of being arrested at an early differentiation stage in the cap 
mesenchyme. It has been shown that in the mouse Wilms tumors Lin28 acted through the 
microRNA Let7 signal transduction pathway (Urbach et al., 2014). However, Lin28 
overexpression in stromal progenitors (Foxd1-Cre), nephron progenitors (Six2-Cre) or 
ureteric buds (Chd16-Cre), did not induce Wilms tumors (Urbach et al., 2014). Microarray 
and IHC analysis showed that Lin28B but not Lin28A was expressed in human Wilms 
tumors and the expression levels of Lin 28B was significantly associated with increased 
severity of tumor progression (Urbach et al., 2014). 
These mouse Wilms tumor models provided useful tools to study the mechanisms of 
Wilms tumor development in vivo; however, in these tumor models the genetic alterations 
were introduced randomly into developing kidney cells, or post-natal kidney cells, or pre-
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metanephric mesenchme cells. It is still not clear what types of cells in the metanephric 
kidney, or at what differentiation state during renal development, initiate the development of 
Wilms tumors. These are the questions that our study specifically addressed. 
 
1.11 Cell Origins of Wilms tumors 
A study of global gene expression array with a large panel of human Wilms tumors has 
identified 5 subsets of Wilms tumors (Table 1) (Gadd et al., 2012). These subsets are 
different in gene expression profiles, histological features, and clinical outcomes (Gadd et 
al., 2012). For example, Subset 1 is characterized by differentiated epithelial histology and a 
gene expression signature corresponding to terminal epithelial differentiation. Clinically, 
patients within this subset had no tumor relapses. On the other hand, Subsets 2-4 are 
characterized by triphasic histology with undifferentiated blastemal cells mixed with epithelial 
and stromal cells, and these tumors had gene expression signatures corresponding to early 
stage of the mesonephric mesenchyme and renal interstitium. Moreover, 10-50% of these 
patients had tumor recurrences. These data suggested that the different Wilms tumor 
subsets arise from cells at different stages of mesenchyme differentiation (Gadd et al., 
2012). Therefore, we hypothesized that the differentiation status of the initially mutated cell 
impacts the formation of different types of Wilms tumors. Addressing this hypothesis will 
help us to understand how the different types of Wilms tumors occur and potentially help us 
to develop improved therapy accordingly.  
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Table 1. Identification of human WT subsets based on 
gene expression array 
Relapse Histology 
 
Signature genes 
 
Subset 1 
(S1) 
0/11 Epithelial 
differentiated  
After MET and in terminally 
differentiated epithelium  
e.g. NOTCH signaling, HOXA11, 
MEIS2 
Subset 2 
(S2) 
2/23 Triphasic, 
muscle 
differentiation 
elements 
Very early mesonephric mesenchyme 
and renal interstitium 
e.g. NFAT and TGFB signaling, 
TWIST1, DLK1, WIF1, MYH3, TTN, 
ACTA1 
Subset 3 
(S3) 
7/21 Similar to S2, 
less muscle 
differentiation 
NFAT, TGFB and RAS signaling 
Subset 4 
(S4) 
6/11 Similar to S2 Similar to S2 
Subset 5 
(S5) 
50/158 Triphasic, mostly 
blastema 
predominant 
Early metanephric mesenchyme 
e.g. SIX1, PAX2, EYA1, HOXA11 
Previously, our lab generated a mouse model of Wilms tumor by using a ubiquitous Cre 
to somatically and mosaically ablate Wt1 at E11.5 in the background of Igf2 over-expression 
(Hu et al., 2010). In this model, Wt1 ablation is essential for the development of mouse 
Wilms tumors. However, it is unclear what cell types were targeted with Wt1 ablation and 
consequently gave rise to tumors. At E11.5, WT1 is expressed in the metanephric 
mesenchyme mainly composed of stromal progenitors and nephron progenitors. In this 
mouse model, when Wt1 is ablated randomly with the ubiquitous Cre, the stromal 
progenitors or the nephron progenitors could have been targeted and serve as promising 
candidates for the tumor initiating cells. To find out the cell origins of Wilms tumors, we 
applied the same approach of generating the mouse tumor model by using Cre-Loxp 
system, but we used progenitor cell-type specific tamoxifen-inducible Cre to introduce 
genetic mutations into specific cellular compartment (stromal progenitor or nephron 
progenitor) in the metanephric mesenchyme. 
 
1.12 Targeting kidney progenitors with the cell-type specific Cre 
The abilities of self-renewal and multipotency in progenitor cells make them a promising 
candidate as tumor initiation cells. To determine whether the kidney progenitors are the 
primary targets for cell transformation, progenitor specific tamoxifen-inducible CreER alleles 
were used. Foxd1GCE was used to target the stromal progenitor and Six2GCE or Cited1Cre was 
used to target the nephron progenitor. Since Wt1 loss-of-function and β-catenin activating 
mutations are often found in Wilms tumors, it is clinically and molecularly relevant to 
introduce these genetic mutations to the mouse and generate mouse Wilms tumors. The 
Cre-LoxP system was applied to induce Wt1 ablation or β-CATENIN stabilization in kidney 
stromal progenitor or nephron progenitor. 
Foxd1GCE (stomal progenitor specific) and Six2GCE (nephron progenitor specific) knock-in 
alleles replace endogenous exon 1 at the initiation codon of Foxd1 or Six2, respectively, 
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with a gene cassette of GFP and tamoxifen inducible Cre (GCE) (Fig. 1.4 A). The 
Foxd1GCE/GCE and Six2GCE/GCE mutant homozygote mice die soon after birth, but the 
heterozygotes are viable and phenotypically normal (Hatini et al., 1996) (Self et al., 2006). 
The Cited1Cre is a BAC transgene in which GFP-CRE expression is under the transcriptional 
control of 190 kb genomic sequence 5’ of the Cited1 gene (Fig. 1.4 A) (Boyle et al., 2008). 
All three Cre lines have been shown to express the CRE recombinase where endogenous 
FOXD1, SIX2 or CITED1 proteins are normally expressed in the fetal kidney. Therefore, with 
the inducible CRE, we could introduce Wt1 ablation or β-CATENIN stabilization in a 
progenitor cell type-specific manner to study cell origins of Wilms tumors. 
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Progenitor-specific Cre constructs 
Foxd1GCEor Six2GCE knock-in allele 
CreERT2-IRESeGFP TetR 
BAC Cited1 locus 
Cited1-Cre BAC transgene 
 
eGFPCreERT2-SV40pA PGK-neo-bpA Exon 1 
Foxd1 or Six2 promoter 
Wt1 
DNA binding domain 
Dysfunctional Wt1 
β-catenin 
Stabilized β-Catenin 
 
Cre 
Figure 1.4 Diagram of progenitor-specific Cre alleles and Wt1 and β-
catenin flox alleles. 
(A)The construct of Foxd1GCEor Six2GCE knock-in alleles. (B) Constructs of Wt1fl 
and Wt1∆ alleles. (C)The construct of β-catenine3fl and β-catenine3∆ alleles. 
Image B is from Gao, F., Maiti, S., Alam, N., Zhang, Z., Deng, J.M., Behringer, R.R., Lecureuil, C., Guillou, F., and Huff, 
V. (2006). The Wilms tumor gene, Wt1, is required for Sox9 expression and maintenance of tubular architecture in the 
developing testis. Proceedings of the National Academy of Sciences of the United States of America 103, 11987-
11992. (Copyright (2006) National Academy of Sciences, U.S.A.)   Image C is from Mucenski, M.L., Nation, J.M., 
Thitoff, A.R., Besnard, V., Xu, Y., Wert, S.E., Harada, N., Taketo, M.M., Stahlman, M.T., and Whitsett, J.A. (2005). 
Beta-catenin regulates differentiation of respiratory epithelial cells in vivo. American journal of physiology Lung cellular 
and molecular physiology 289, L971-979. Figures used with permission. 
A 
B 
C 
1.13 Wt1 in kidney development and Wilms tumor 
1.13.1 Wt1 is a transcription factor 
Wt1 is a transcription factor and RNA binding protein. The human WT1 gene is about 50 
kb in size, encoding a 3 kb mRNA with 10 exons (Call et al., 1990). The WT1 protein has 
four Kruppel-type zinc fingers at the carboxyl terminus, which are involved in DNA binding 
(Call et al., 1990). Exons 8-9 encode the second and third DNA binding domains which are 
critical for Wt1 functions. To disrupt Wt1 function, loxP sites were inserted flanking exons 8-
9 and, in the presence of CRE recombinase, the in-frame deletion of Exons 8-9 results in 
truncated, inactive Wt1 (Fig. 1.4 B) (Gao et al., 2006). 
WT1 has many isoforms due to alternative translational start sites, alternative splicing 
and RNA editing (reviewed in (Hohenstein and Hastie, 2006)). Alternative splicing results in 
the inclusion or exclusion of exon5 and of 3 amino acids (lysine-threonine-serine, KTS) at 
the 3 prime end of exon 9 (Hohenstein and Hastie, 2006). The KTS- isoform binds to DNA 
with a high affinity and functions as a transcription factor (Hohenstein and Hastie, 2006). 
The KTS+ Wt1 isoform has a low DNA binding affinity, but interacts with RNA preferentially 
(Hohenstein and Hastie, 2006). These various isoforms remain in relative proportion in fetal 
kidney (Hohenstein and Hastie, 2006).   
WT1 can transcriptionally activate or repress downstream target genes, depending on 
the cellular context and interacting proteins. Some of the downstream targets include Egfr 
(Englert et al., 1995), Igf2 (Drummond et al., 1992), Pax2 (Ryan et al., 1995), Wnt4 (Sim et 
al., 2002) and Amphiregulin (Lee et al., 1999), which are all important in kidney 
development. A systematic genome-wide study was carried out to identify Wt1 targets 
controlling cell function and differentiation of nephron progenitors (Hartwig et al., 2010). This 
study analyzed embryonic kidneys at E18.5 and used the approaches of chromatin 
immunoprecipitation and mouse promoter microarray. The defined targets associated with 
renal agenesis are WNT inhibitor Cxxc5, MAP kinase signaling effector Erk1, epigenetic 
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regulators such as Rest and Jmdj3, and proteins involved in TGFβ/BMP signaling (Hartwig 
et al., 2010).  
 
1.13.2 WT1 is a tumor suppressor in Wilms tumors 
WT1 is defined as a tumor suppressor in Wilms tumors given that loss of function of 
WT1 predisposes patients to Wilms tumor development. Predisposition to Wilms tumor is 
observed in four congenital syndromes, WAGR, Denys-Drash, Beckwith-Wiedemann and 
Frasier syndromes, most of which have genitourinary defects (Mrowka and Schedl, 2000), 
and all of which involve alterations of chromosome 11p13-15. Germ-line WT1 mutations are 
associated with bilateral tumors and an early age at diagnosis, but there is no difference in 
overall survival between patients with and without WT1 mutations (Discenza and Pelletier, 
2004). 
However, many Wilms tumors with wild type WT1 overexpress WT1. High expression of 
wild type WT1 in Wilms tumor result in the arrest of undifferentiated mesenchymal cells at 
early differentiation and suggests that factors controlling the WT1 expression are preserved 
in tumors. WT1 is also overexpressed in most acute myelogenous leukemia, acute 
lymphoblastic leukemia, chronic myelogenous leukemia (CML), and myelodysplastic 
syndrome (MDS) (Rosenfeld et al., 2003). In breast cancer, WT1 has been implicated as an 
oncogene since its high expression is associated with poor prognosis (Miyoshi et al., 2002). 
WT1 plays different roles in tumor development of different kinds of cancers. 
 
1.13.3 Wt1 is required for nephrogenesis 
WT1 plays an essential role in kidney development. Wt1 has been shown to have 
different functions at different stages of kidney development (Elizabeth, 2014). In the 
developing kidney, Wt1 is weakly expressed in the intermediate mesoderm and metanephric 
mesenchyme (Armstrong et al., 1993). The expression of WT1 increases in the proximal 
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segment of the comma-shaped body and S-shaped body, the precursor of glomerular 
podocytes (Grubb et al., 1994). Then its expression is restricted to the podocytes of 
nephrons (Grubb et al., 1994).  
Wt1 is required for cell survival in the intermediate mesoderm, as Wt1 knock-out in mice 
led to cell apoptosis in the intermediate mesoderm and the metanephric mesenchyme, 
resulting in disruption in urogenital development (Kreidberg et al., 1993). In the metanephric 
mesenchyme, Wt1 is essential for the mesenchyme to epithelial transition (Hu et al., 2010). 
Conditional ablation of Wt1 in the metanephric mesenchyme at E11.5 resulted in lack of 
condensation of the mesenchyme around the ureteric bud tips, expansion of the 
mesenchymal region, and blocked mesenchyme to epithelia transition (Hu et al., 2010). The 
expanded mesenchyme caused by Wt1 deletion arrested before the MET makes the 
mesenchymal cells at the pre-MET stage a very likely candidate for tumor development 
(Elizabeth, 2014). In the metanephric mesenchyme, Wt1 transcriptionally activates the 
expression of Wnt4 and thus stimulates epithelial differentiation (Sim et al., 2002). In the 
mature nephron, Wt1 is highly expressed in the podocytes, and reduced expression of Wt1 
causes the accumulation of matrix in the basement membrane, thus leading to crescentic 
glomerulonephritis or mesangial sclerosis (Guo et al., 2002).  
Wt1 is expressed in the metanephric mesenchyme including stromal progenitors and 
nephron progenitors and it regulates cell apoptosis, survival and MET during kidney 
development. However, its specific function in each renal progenitor cell type remains 
unclear. Using the progenitor-specific Cre to ablate Wt1 in the mouse, we can dissect out its 
in vivo effects on nephrogenesis in either stromal progenitor or nephron progenitor and this 
knowledge would help us understand the mechanisms by which Wt1 mutations predispose 
to the development of Wilms tumors. 
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1.14 WNT/β-CATENIN in kidney development and Wilms tumor 
1.14.1 WNT/β-CATENIN signaling 
The WNT/β-CATENIN signal transduction pathway is critical in embryogenesis and is 
often associated with cancer development. WNT proteins are a family of secreted 
glycolipoproteins that interact with the receptors of the FRIZZLED proteins and the LDL 
receptor-related proteins 5 and 6 LRP5/6) (MacDonald et al., 2009). The WNT ligands act 
through β-CATENIN dependent (canonical) pathways or β-CATENIN independent (non-
canonical) pathways. The non-canonical pathways include the Planar Cell Polarity (PCP) 
pathway and the WNT/Ca2+ pathway (Komiya and Habas, 2008).  
In the canonical pathway, β-CATENIN is the mediator of WNT ligand induced signaling. 
Without WNTs, β-CATENIN is susceptible to protein degradation by the APC complex 
composed of the scaffolding protein AXIN, the tumor suppressor adenomatous polyposis 
coli protein (APC), casein kinase 1 (CK1), and glycogen synthase kinase 3 (GSK3) 
(reviewed in (MacDonald et al., 2009)). Initially β-CATENIN binds to AXIN, then β-CATENIN 
is phosphorylated by CK1 at Ser45 in β-catenin exon 3, and is subsequently phosphorylated 
by GSK3 at Ser33, Ser37 and Ser41 (reviewed in (Voronkov and Krauss, 2013)). CK1 and 
GSK3 also phosphorylate APC, and phosphorylated APC has a higher affinity for β-
CATENIN, resulting in the transfer of β-CATENIN to APC from AXIN. The N-terminal 
phosphorylated β-CATENIN in the APC complex is exposed to ubiquitinase β-TrCP and 
subjected to proteasomal degradation (reviewed in (Voronkov and Krauss, 2013)). WNT 
ligands, such as WNT9 and WNT4, bind to the receptor complex LRP5/6-Frizzled and the 
complex recruits the scaffold proteins DISHEVELLED and AXIN, thus inhibiting AXIN-
mediated β-CATENIN phosphorylation and the subsequent β-CATENIN degradation 
(reviewed in (Voronkov and Krauss, 2013)). Thus, β-CATENIN is stabilized and accumulates 
in the cytoplasm. The accumulated β-CATENIN is translocated to the nucleus where it 
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interacts with transcription repressor complex the TCF/LEF, activating the expression of 
downstream targets (reviewed in (MacDonald et al., 2009)). With the genetic in-frame 
deletion of exon3 (Fig. 1.4 C), β-catenin is not susceptible to phosphorylation and is 
therefore stabilized, thus activating downstream oncogenic events (Harada et al., 1999).  
 
1.14.2 WNT/β-CATENIN in renal progenitors 
β-CATENIN signaling is critical in nephron progenitors. Deletion of β-catenin in nephron 
progenitors using the Six2-Cre transgene led to failed formation of renal vesicles and no 
expression of induction markers in renal vesicles such as Fgf8, Wnt4, Pax8 and Lhx1 (Park 
et al., 2007). β-CATENIN activation stimulated nephron progenitors to go through MET and 
ectopically express markers of renal vesicles (Park et al., 2007). Thus, β-CATENIN is 
necessary and sufficient to initiate MET induction in nephron progenitors. However, a 
constant high level of β-CATENIN activity in nephron progenitors did not result in complete 
epithelial differentiation such as the formation of E-CADHERIN expressing epithelium (Park 
et al., 2007). Therefore, transient activation of β-catenin is required to induce differentiation 
of nephron progenitor to renal vesicle stage, but to further epithelialize, β-CATENIN activity 
has to be reduced and fine-tuned (Park et al., 2007). β-CATENIN is activated by WNT9B 
from the ureteric bud and WNT9B activates WNT4 in the induced nephron progenitor to 
increase β-CATENIN signaling (Karner et al., 2011). β-CATENIN acts through the Tcf/Lef 
transcriptional program to maintain the survival, proliferation and early differentiation of 
nephron progenitors (Schmidt-Ott and Barasch, 2008). To promote the differentiation of the 
nephron progenitor, nuclear β-CATENIN is increased by stromal cells in the niche through 
FAT4-HIPPO signaling (Das et al., 2013). SIX2 counteracts β-CATENIN initiated 
differentiation signals via TCF/LEF complex to maintain nephron progenitor self-renewal 
(Park et al., 2012). 
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For the stromal progenitors, β-CATENIN has been shown to be expressed in the cell 
membrane (Das et al., 2013) and is likely involved in cell-cell adhesion junctions. 
Conditional deletion of β-catenin using Foxd1-Cre did not show any abnormality in nephron 
induction or ureteric bud branching, however, the mutants had slightly thicker cortices and 
failed development of the medulla (Yu et al., 2009). Wnt2b is expressed in the stromal 
mesenchyme, but Wnt2/Wnt2b double knock out mice did not show abnormal phenotype in 
the kidney (Goss et al., 2009). These results suggested that WNT/β-CATENIN did not seem 
to be essential for the functions of stromal progenitors, but the specific roles of WNT/β-
CATENIN signaling in the stromal progenitors still remains to be investigated. 
 
1.14.3 WNT/β-CATENIN in Wilms tumors 
High activity of β-CATENIN is associated with numerous cancers. β-catenin stabilization 
mutations or nuclear accumulation of β-CATENIN is often found in Wilms tumors with 
stromal histology and ectopic mesenchymal elements such as myogenesis or 
chondrogenesis (Fukuzawa et al., 2009). Wilms tumors with β-catenin mutations showed 
high expressions of β-catenin targets PITX2 and APCDD1, Wnt/β-catenin extracellular 
inhibitors, muscle-related genes and oncogenes in retinoic acid and RAS pathways (Zirn et 
al., 2006). In Wilms tumors, β-CATENIN stabilization mutations are frequently associated 
with WT1 loss of function mutations (Maiti et al., 2000). Another genetic study of Wilms 
tumors also found β-CATENIN stabilization mutations were detected only in WT1 mutated 
Wilms tumors (Li et al., 2004). These tumors also expressed high level of genes such as β-
CATENIN/TCF targets, WNT inhibitors, myogenic differentiation factors and TGF-β signaling 
(Li et al., 2004).  
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Summary 
Wilms Tumor is thought to arise from the undifferentiated metanephric mesenchyme, 
and the observation of distinctive subsets of tumors suggests that each subset arises from 
cells at different stages of differentiation (Gadd et al., 2012). In this thesis, by using mouse 
genetic models, we applied progenitor-specific CreER to somatically and mosaically introduce 
Wt1 ablation in the context of Igf2 biallelic expression or β-catenin activation into stromal 
progenitors and nephron progenitors. We investigated whether Wilms tumors could arise 
from fetal kidney cells at distinct differentiation statuses and whether specific kidney 
progenitor populations could produce different types of Wilms tumors with respect to tumor 
initiation, growth and pathology. We also studied the impact of different types of gene 
mutations on the development of Wilms tumors. Moreover, with the same approach, we 
studied the effects of Wt1 ablation on kidney development to understand how Wt1 ablation 
predisposes to malignant transformation. These results could provide insights into the cell 
origins of Wilms tumor and the mechanisms of tumor initiation and development and also 
help us to understand the functions of Wt1 in stromal progenitors and nephron progenitors. 
Potentially the mouse model studies will help us to develop improved therapies that target 
different types of tumors specifically and trigger the most effective responses according to 
the tumor cell origins or tumor types. 
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Chapter 2: Materials and Methods 
2.1 Mice 
The mice were housed and handled according to the guidelines of The University of 
Texas MD Anderson Cancer Center Institutional and Animal Care and Use Committee. All of 
the mice were maintained on a C57BL/6J x 129/SvEv mixed genetic background. 
Littermates of the mutant mice were used as controls. The mice were genotyped via 
standard PCR analysis of genomic DNA isolated from the tails as described previously (Gao 
et al., 2006; Harada et al., 1999; Hayashi and McMahon, 2002; Leighton et al., 1995). 
Foxd1GCE/+, Six2GCE/+, Cited1Cre, R26tdTomato/tdTomato, Wt1+/-, Wt1fl/fl, β-catenine3fl/e3fl, and H19-
/- mice described previously (Humphreys et al., 2010) (Kobayashi et al., 2008) (Boyle et al., 
2008) (Kreidberg et al., 1993) (Gao et al., 2006) (Harada et al., 1999) (Leighton et al., 1995) 
were used in this study. We bred the Foxd1GCE/+ or Six2GCE/+ or Cited1Cre with Wt1+/- mice to 
generate Foxd1GCE/+; Wt1+/- or Six2GCE/+; Wt1+/- or Cited1Cre; Wt1+/- male mice. Wt1fl/fl mice 
were bred with β-catenine3fl/e3fl or H19-/- or R26tdTomato/tdTomato or R26 βgal/βgal mice for a few 
generations to generate females that were Wt1fl/fl; β-catenine3fl/e3fl or Wt1fl/fl; H19-/- or Wt1fl/fl; 
R26tdTomato/tdTomato or Wt1fl/fl; R26 βgal/βgal. 
 
2.1.1 β-gal reporter analysis of Foxd1GCE and Six2GCE mice 
Tamoxifen was dissolved in corn oil and injected at E11.5 or E14.5 intraperitoneally into 
pregnant mice (R26βgal/ βgal) mated with Foxd1GCE/+ or Six2GCE/+ male mice. Kidneys (Cre+; 
R26βgal/+) were analyzed at E14.5 and E19.5 with littermates (R26βgal/+) as controls. When 
tamoxifen was injected at E11.5, kidney sections at E14.5 showed that both Foxd1GCE and 
Six2GCE Cre alleles were effective to induce recombination (Fig. 3.2, A and C).  However, 
when tamoxifen injection time was at E14.5, kidney sections at E19.5 showed that only 
Six2GCE but not Foxd1GCE was efficient in inducing recombination (Fig. 3.2, B and D). This 
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result provided us information on the conditions of tamoxifen injection time for the mouse 
tumor cohort generation. To target progenitor cells effectively, tamoxifen was administered 
at E11.5 for Foxd1GCE cohort generation, but at E11.5 or E14.5 for Six2GCE cohort 
generation. 
 
2.1.2 tdTOMATO reporter analysis of Foxd1GCE, Six2GCE and Cited1Cre mice 
To analyze the efficiency of the Cre, Foxd1GCE/+, Six2GCE/+ or Cited1Cre/+ mice were 
crossed with tdTomato reporter mice (R26tdTomato/tdTomato) expressing the loxP-Stop-loxP 
tdTomato transgene. Cre+; R26tdTomato/+ embryos were induced with tamoxifen (1 or 3 mg / 
40g body weight) at E11.5 or E14.5 during mid-gestation. CITED1 expression does not 
become robust until E14.5, therefore we selected E14.5 and E17.5 as the time point for 
tamoxifen induction in Cited1Cre mice. Embryonic kidney sections were prepared for 
histology analysis at E19.5. 
 
2.1.3 Generation of the mouse tumor cohorts with progenitors targeted 
To generate the tumor cohorts, Cre+; Wt1+/- males were bred with females Wt1fl/fl;H19-/- 
(Fig. 2.1 A) or Wt1fl/fl; β-cateninex3fl/fl (Fig. 2.1 B) or β-cateninex3fl/ex3fl (Fig. 2.1 C). Pregnant 
mice were injected with tamoxifen (0.5, 1 or 3 mg / 40g BW) intraperitoneally to activate the 
inducible CRE in fetal kidney progenitors (Table 3). For Foxd1GCE, tamoxifen was 
administered at E11.5. For Six2GCE, tamoxifen was administered at E11.5 or E14.5. The 
Cited1Cre transgene is expressed in the liver at E14.5 but not at E17.5, and β-CATENIN 
activation in the CITED1+ liver progenitors at E14.5 led to the development of hepatocellular 
carcinoma and hepatoblastoma in 90% of mutants at early ages (Mokkapati et al., 2014). To 
avoid this competing phenotype and cause of death for our Wilms tumor study, E17.5 was 
selected as the time point for tamoxifen injection for the Cited1Cre-Wt1-β-catenin cohort 
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generation. Wt1 ablation by Cited1Cre and Igf2 up-regulation did not result in a detectable 
liver phenotype with tamoxifen injection at E14.5, therefore we injected tamoxifen at E14.5 
for Cited1Cre-Wt1-Igf2 cohort generation. Mutant mice Cre+; Wt1+/fl or Wt1-/fl or Wt1+/+; β-
cateninexon3+/fl or Cre+; Wt1-/fl; H19+/-m were monitored for tumor development. 
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X 
Cre / +; Wt1 - / fl; β-catenine3fl/+ 
Cre / +; Wt1 + / - Male Wt1 fl / fl; β-catenine3fl/e3fl Female 
Cre / +; Wt1 + / fl; β-catenine3fl/+ 
Wt1 - / fl; β-catenine3fl/+ 
Tumor monitor 
Control 
Wt1 + / fl; β-catenine3fl/+ 
Tamoxifen injection  
S-Wt1-βCat or 
C-Wt1-βCat  or 
F-Wt1-βCat  
B 
X 
Six2GCE/+; β-catenine3fl/+ 
Six2GCE/+ Male β-catenine3fl/e3fl Female 
β-catenine3fl/+ 
Tumor monitor 
Control 
Tamoxifen injection  
S-βCat 
C 
Figure 2.1 Schematic diagram of mouse crosses for cohort generation 
X 
Cre / +; Wt1 - / fl; H19 + / -m 
Cre / + X Wt1 + / - 
Cre / +; Wt1 + / - Male Wt1 fl / fl; H19 - / - Female 
Cre / +; Wt1 + / fl; H19 + / -m 
Wt1 - / fl; H19 + / -m 
Tumor monitor 
Control 
Wt1 + / fl; H19 + / -m 
Tamoxifen injection  
F-Wt1-Igf2 or 
S-Wt1-Igf2 or 
C-Wt1-Igf2 
A 
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2.2 Histological, immunohistochemical, and Western blot analysis 
Tumor and kidney tissue specimens were fixed in 4% paraformaldehyde, embedded in 
paraffin, and cut into 5-µm sections. Hematoxylin and Eosin (H&E), immunohistochemical 
and immunofluorescent staining and Western blot analysis of proteins were performed as 
described previously (Hu et al., 2010). Antibodies specific for WT1 (sc-192, Santa Cruz 
Biotechnology) (1:100), KI67 (ab15580, Abcam) (1:200), pHH3 (06-570, Upstate 
Biotechnology) (1:200), β-CATENIN (610154 BD Biosciences) (1:200), DLK1 (sc-8624 
Santa Cruz Biotechnology) (1:100), CITED1 (9219 FisherScientific) (1:100), SIX2 (11562-1-
AP, Proteintech) (1:100), PAX2 (PRB-276P Covance) (1:200), NCAM (C9672 Sigma) 
(1:200), E-CADHERIN (3195, Cell Signaling Technology) (1:200), K-CADHERIN (ab79005, 
Abcam) (1:200), VIMENTIN (V2258 Sigma) (1:100), COLLAGEN IV (AB756P Chemicon) 
(1:100), CYCLIN D1 (sc-753 Santa Cruz Biotechnology) (1:100), C-MYC (9E10 Santa Cruz 
Biotechnology) (1:100), ERK 1/2 (4377, Cell Signaling Technology) (1:100), pERK 1/2 
(4376, Cell Signaling Technology) (1:100), and pAKT (4051S Cell Signaling Technology) 
(1:100) were used. 
 
2.3 β-gal staining 
Freshly dissected kidneys or slides made from OCT-embedded frozen tissues were fixed 
in fixation buffer (0.2% glutaraldehyde, 2% formalin, 5 mM EGTA, 2 mM MgCl2 in 0.1 M 
phosphate buffer) for 30 min to 1 hour at room temperature. Samples were rinsed in rinse 
buffer (0.1% sodium deoxycholate, 0.2% NP40, 2 mM MgCl2 in 0.1 M phosphate buffer). 
Then samples were stained at 4oC overnight in staining solution (1 mg/ml X-gal, 5 mM K 
ferricyanide and 5 mM ferrocyanide in rinse buffer). After staining, tissues or slides were 
rinsed and postfixed in 4% paraformaldehyde. Slides were counterstained with eosin for 
histological analysis. 
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2.4 Kidney rudiment culture 
Pregnant mice were injected intraperitoneally at E11.5 with tamoxifen at a dose of 
3mg/40g body weight. Kidney rudiments were dissected out of embryos at E12.5 or E13.5. 
Mutant and control rudiments were cultured on a trans-well plate (Transwell) with media 
containing 1μM 4-OH-TM (Sigma-Aldrich), 10% fetal bovine serum (Sigma-Aldrich) and 
DMEM (Sigma-Aldrich 10-017-CV) at 37oC as described previously (Hu et al., 2010). During 
culture, live imaging pictures of the rudiments were taken every day with an inverted 
microscope (Olympus IX71). After culturing for 3 days, the cultured rudiments were rinsed in 
PBS and fixed in methanol for whole-mount immunofluorescence staining (Hu et al., 2010).  
 
2.5 Reverse-phase protein array 
Protein was extracted from murine tumors and normal kidney tissues and the 
concentration of the protein extracts were calculated with Bradford assay (Bio-Rad). The 
samples were analyzed by reverse-phase protein arrays (RPPA) analysis as described 
previously (Hu et al., 2010). RPPA is a high-throughput method to detect protein expression 
with 135 antibodies against common onco-proteins and tumor suppressors 
(mdanderson.org). Briefly, protein samples were denatured by SDS buffer, loaded on 
nitrocellulose-coated slides, and probed with antibodies. The signals from binding interaction 
were detected by DAB colorimetric reaction. 
 
2.6 Fluorescence-activated cell sorting analysis (FACS) 
We administered 1 or 3 mg (per 40g body weight) of tamoxifen to pregnant mice in utero 
at E11.5, E14.5 or E17.5. Single-cell suspensions from fetal kidneys harvested at E15.5 or 
E19.5 from Foxd1GCE/+; R26tdTomato/+, Six2GCE/+; R26tdTomato/+ and Cited1Cre/+; R26tdTomato/+ 
embryos were prepared as previously described (Kobayashi et al., 2008). Briefly, kidney 
tissues were trypsinized at 37oC for 3-5 minutes and mechanically disintegrated into single 
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cells by repeated pipetting up and down in DMEM with 10% FBS. The cell suspensions 
were washed with PBS containing 2% FBS and filtered through 70 µm pore filter (BD 
Falcon). Cells expressing tdTomato were isolated by using a BD FACS Aria high-speed 
digital cell sorter (BD Biosciences). Cell suspensions from littermate kidneys without Cre 
served as negative controls. 
 
2.7 Quantitative real-time PCR 
Tumor or kidney tissue specimens or isolated tdTomato-positive cells were flash-frozen 
in liquid nitrogen. RNA was extracted from specimens or cell pellets using the RNAqueous-
4PCR kit (Ambion AM1914). The concentration of RNA was determined using the Nanodrop 
spectrophotometer (Nanodrop ND-1000). RNA was then converted to cDNA using reverse 
transcription reagents (Applied Biosystems). Real-time (RT)-PCR was performed using 
SYBR Green PCR Master Mix (Applied Biosystems) with a 7900HT sequence detection 
system (Applied Biosystems). 
 
2.8 Statistical analysis 
The Student t-test or analysis of variance was used to analyze RT-PCR results. Results 
were presented as mean value with standard deviation. P-values less than 0.05 were 
considered statistically significant.  
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2.9 qRT-PCR Primers 
Gene 5' to 3'  
Eya1-F CATAGCCGACTGAGTGGTAGT (Basta et al., 2014) 
Eya1-R GCTCTGTTTTAACTTCGGTGCC  
Osr1-F TACTCTTTCCTTCAGGCAGTGA  
Osr1-R GATCGAGGCAAGTGCATGG  
Hoxa11-F TTTGATGAGCGTGGTCCCTG PrimerBank ID 6754226a1 
Hoxa11-R AGGAGTAGGAGTATGTCATTGGG  
Pax2-F AAGCCCGGAGTGATTGGTG  
Pax2-R CAGGCGAACATAGTCGGGTT  
Wnt4-F AGACGTGCGAGAAACTCAAAG  
Wnt4-R GGAACTGGTATTGGCACTCCT  
CyclinD1-F GCGTACCCTGACACCAATCTC PrimerBank ID 6680868a1  
CyclinD1-R CTCCTCTTCGCACTTCTGCTC  
Jag1-F CCTCGGGTCAGTTTGAGCTG PrimerBank ID 7305197a1  
Jag1-R CCTTGAGGCACACTTTGAAGTA  
E-cadherin-F ACTGTGAAGGGACGGTCAAC  
E-cadherin-R GGAGCAGCAGGATCAGAATC  
Titin-F TCAAGGAGGAAGCGTCCAAAG PrimerBank ID 19388004a1 
Titin-R GACTTCTTCGGATGCCTGTGA  
Actin a1-F CCCAAAGCTAACCGGGAGAAG PrimerBank ID 33563240a1 
Actin a1-R CCAGAATCCAACACGATGCC  
Axin2-F TGACTCTCCTTCCAGATCCCA  
Axin2-R TGCCCACACTAGGCTGACA  
Wif1-F TCTGGAGCATCCTACCTTGC PrimerBank ID 6755999a1 
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Wif1-R ATGAGCACTCTAGCCTGATGG  
Cyclin E-F GTGGCTCCGACCTTTCAGTC  
Cyclin E-R CACAGTCTTGTCAATCTTGGCA  
Cxxc4-F CTGCCCGCAGAATCATTCCT  
Cxxc4-R CAGACGCCACAGTTGATGAG  
Pitx2-F ACCCCGGCTATTCGTACAAC PrimerBank ID 1724116a1  
Pitx2-R GAGGACAGGGGATTGACGTTC  
Dlk1-F AGTGCGAAACCTGGGTGTC PrimerBank ID 12838136a1 
Dlk1-R GCCTCCTTGTTGAAAGTGGTCA  
Hmga2-F GAGCCCTCTCCTAAGAGACCC PrimerBank ID 30017353a1 
Hmga2-R TTGGCCGTTTTTCTCCAATGG  
Dkk2-F CTGATGCGGGTCAAGGATTCA PrimerBank ID 31560347a1 
Dkk2-R CTCCCCTCCTAGAGAGGACTT  
NCAM-F ACCACCGTCACCACTAACTCT  
NCAM-R TGGGGCAATACTGGAGGTCA  
Pax8-F ATGCCTCACAACTCGATCAGA  
Pax8-R ACAATGCGTTGACGTACAACTT  
Stim1-F TGACAGGGACTGTACTGAAGATG  
Stim1-R TATGCCGAGTCAAGAGAGGAG  
Nfat4-F CAAGATGGAAGACCTCATTGG  
Nfat4-R GGGAGGAACTTCAAGGACAA  
CD15-F TGGTACTACGCGTGTTCGAC  
CD15-R CCAGGGCTTTGCCAGTTA  
CD248-F CAACGGGCTGCTATGGATTG  
CD248-R GCAGAGGTAGCCATCGACAG  
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Synaptopodin-F GGAAAGTGATGACAGCCAGTG  
Synaptopodin-R TTTTCGGTGAAGCTTGTGCT  
Dnmt1-F AAGAATGGTGTTGTCTACCGAC  
Dnmt1-R CATCCAGGTTGCTCCCCTTG  
Sall1-F CTCAACATTTCCAATCCGACCC  
Sall1-R GGCATCCTTGCTCTTAGTGGG  
Meox2-F TGTCCTACCCCGAACTCTCC  
Meox2-R GTGCCAGTTGCTTTGCAGA  
Pax3-F TTTCACCTCAGGTAATGGGACT  
Pax3-R GAACGTCCAAGGCTTACTTTGT  
(Spandidos et al., 2010) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
Chapter 3: Results 
Part I: Impact of differentiation state and genetic context on the development of 
mouse Wilms tumors 
3.1 Expression of the progenitor-specific Cre alleles as determined by GFP reporter 
expression 
To determine what cells in the undifferentiated renal mesenchyme are able to generate 
Wilms tumors, we used progenitor-specific tamoxifen-inducible Cre (stromal progenitor 
Foxd1GCE and nephron progenitor Six2GCE and Cited1Cre) to introduce gene mutations 
somatically and mosaically into specific cellular compartments of the mouse fetal kidneys.  
The expression of CRE and GFP (Cre-Gfp) are both driven by the same promoter. We 
examined the Cre-Gfp cassette expression driven by the progenitor-specific gene promoter 
at E14.5 by assessing the GFP expression. The Foxd1GCE-Gfp cassette was expressed in 
the stromal progenitors surrounding the cap mesenchyme (Fig. 3.1B). The Six2GCE-Gfp 
cassette was expressed in the uninduced and induced cap mesenchyme in a bracket 
pattern (Fig. 3.1D). The Cited1Cre-Gfp cassette was expressed only in the uninduced cap 
mesenchyme (Fig. 3.1, E and F).  
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Figure 3.1 Cre-GFP expression under the control of progenitor-specific 
gene promoter.  
 
Kidneys from Foxd1GCE/+ (A and B), Six2GCE/+ (C and D) and Cited1Cre/+ (E 
and F) at E14.5. (A and C) Bright field images of whole kidneys. (B) GFP 
image of kidney from Foxd1GCE/+ embryo showed that Foxd1-Cre-GFP was 
expressed  in the stromal progenitors surrounding the cap mesenchyme. (D) 
GFP image of kidney from Six2GCE/+ embryo showed that Six2-Cre-GFP was 
expressed in the uninduced and induced cap mesenchyme. (E-F) Anti-GFP 
antibody staining of kidney sections from Cited1Cre/+ embryo showed that 
Cited1-Cre-GFP was expressed in the uninduced cap mesenchyme. Dapi 
staining shows the nuclear staining of cells. 
Six2GCE/+  Foxd1GCE/+  Cited1Cre/+  
A 
B 
C 
D 
E 
F 
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3.2 Validation of the fate mapping of the progenitor-specific Cre alleles 
We then confirmed the cell fate of the progenitors expressing specific CRE using a β-gal 
reporter construct. As reported previously, the stromal progenitors (FOXD1+) generated 
interstitial cells, pericytes and mesangial cells (Fig. 3.2, A and B). The nephron progenitors 
(SIX2+) gave rise to epithelial cells including comma-shaped bodies, S-shaped bodies, 
podocytes, glomeruli, proximal tubules and distal tubules (Fig. 3.2, C and D). These results 
confirmed the cell lineage of Foxd1GCE/+ labeled stromal progenitors and Six2GCE/+ marked 
nephron progenitors in the mixed genetic background of our mouse strains.  
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Figure 3.2 Lineage tracing of the stromal (Foxd1+) progenitors and 
nephron (Six2+) progenitors. 
 
β-gal staining of kidney sections from Foxd1GCE/+; R26βgal/+ (A and B) and 
Six2GCE/+; R26βgal/+ (C and D). Kidney sections at E14.5 (A) and E19.5 (B) 
showed that β-gal labeled cells derived from Foxd1GCE included interstitial 
cells (I), pericytes (p) and mesangial cells (m).  
Kidney sections at E14.5 (C) and E19.5 (D) showed that β-gal labeled cells 
derived from Six2GCE were in comma-shaped bodies (cb), S-shaped bodies 
(sb), podocytes (pd), glomeruli (g), proximal tubules (pt) and distal tubules 
(dt). Tm: tamoxifen. Scale bars: 100 µm. 
Six2GCE/+; R26βgal/+  Foxd1GCE/+; R26βgal/+  
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3.3 Estimation of the efficiency of the progenitor-specific CRE 
The efficiency of the progenitor-specific CRE recombinase was analyzed at E19.5 by 
using the fluorescent protein reporter, tdTOMATO. Similar results were observed using the 
tdTOMATO reporter and β-gal staining. With tamoxifen injection at E11.5, tdTOMATO 
induced by Foxd1GCE was expressed in stromal progenitors, interstitial cells and pericytes 
(Fig. 3.3 A). Six2GCE was efficient in recombination when tamoxifen injection was at either 
E11.5 or 14.5 (Fig. 3.3 B and C). Six2GCE induced tdTOMATO was expressed in nephron 
progenitors, renal vesicles, comma-shaped bodies, S-shaped bodies and tubules (Fig. 3.3 B 
and C). Cited1Cre/+ was also efficient in recombination with tamoxifen injection at either 
E14.5 or 17.5 (Fig. 3.3 D and E). Cited1Cre induced tdTOMATO expression was mainly in 
nephron progenitors and early stage of epithelial differentiation structures (Fig. 3.3 B and C), 
due to the short time window between tamoxifen injection and reporter expression analysis. 
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A B 
E 
D 
tdTomato / Dapi 
Six2GCE  
1mg Tm at E17.5 
3mg Tm at E14.5 
3mg Tm at E14.5 
3mg Tm at E11.5 1mg Tm at E11.5 
Foxd1GCE  Cited1Cre  
Figure 3.3 TdTomato reporter showing efficient recombination and 
specific cell fate from Foxd1GCE, Six2GCE and Cited1Cre. 
 
tdTomato reporter imaging of kidney sections at E19.5 from Foxd1GCE/+ (A), 
Six2GCE/+ (B and C) and Cited1Cre (D and E) after tamoxifen (Tm) injection 
with indicated conditions. Scale bars: 200 µm. 
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C 
To quantitatively assess the frequency of recombination by the CRE recombinase, we 
counted the percentage of tdTOMATO labeled cells in the whole kidneys from Cre+; 
R26tdTomato/+ embryos by FACS assay. Single-cell suspensions from fetal kidneys harvested 
at E15.5 or E19.5 were sorted for tdTOMATO expression (Table 2). tdTOMATO+ cells were 
easily distinguished and separated from the tdTOMATO- cells as shown in a representative 
FACS sorting plot (Fig. 3.4 A). FACS analysis at E19.5 showed that about 7% of cells were 
labeled with tdTOMATO by Foxd1GCE, 30-34% by Six2GCE, and 5-7% by Cited1Cre (Table 2 
and Fig. 3.4B). With Cited1Cre, tamoxifen injection at E14.5 or E17.5 did not seem to affect 
the frequency of tdTOMATO+ cells (6.8% and 5.1% respectively), although the frequency 
was slightly higher when tamoxifen injection was earlier (Table 2 and Fig. 3.4 B). We also 
compared the percentage of tdTOMATO+ cells when analyzed at different time points with 
the same conditions of tamoxifen administration. For Foxd1GCE and Six2GCE, tdTOMATO+ 
cells were assessed at E15.5 and E19.5, and a very similar percentage of tdTOMATO 
expressing cells were detected (7.1% vs. 7% and 33.7% vs. 30.2%) (Table 2 and Fig. 3.4 
B). Altogether, efficient recombination was achieved with the tamoxifen injection conditions 
we used in this study for Foxd1GCE, Six2GCE and Cited1Cre. 
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Cre 
Time point of  
Tm injection 
Tm dosage FACS 
tdTomato+ 
cells % 
Foxd1GCE E11.5 3 mg 
E15.5 7.1 
E19.5 7.0 
Six2GCE 
E11.5 1 mg 
E15.5 33.7 
E19.5 30.2 
E14.5 3 mg E19.5 30.0 
Cited1Cre  
E14.5 1 mg E19.5 6.8 
E17.5 1 mg E19.5 5.1 
Table 2. Conditions of Tamoxifen injection used to quantify 
the Cre efficiency and percentages of tdTomato+ cells 
targeted by progenitor-specific Cre 
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Figure 3.4 FACS analysis of embryonic kidney cell suspension for 
tdTomato+ cells. 
 
(A) Representative dot-plot of tdTomato+ cells from single cell suspension 
of Cited1Cre; R26tdTomato/+  kidney at E19.5 after 3 mg/40g BW Tm 
treatment at E14.5. (B) FACS analysis for tdTomato+ cells showing efficient 
targeting of stromal progenitor by Foxd1GCE and of nephron progenitor by 
Six2GCE or Cited1Cre. In the table below the bar graph, the 1st row shows 
the amount of mg of tamoxifen injected per 40g body weight, the 2nd row 
shows the injection time and the 3rd row shows the harvest time. 
A B 
Tm 1 1 3 1 1 3 3 
E 11.5 11.5 14.5 14.5 17.5 11.5 11.5 
E 15.5 19.5 19.5 19.5 19.5 15.5 19.5 
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3.4 Mutated renal stromal progenitors did not result in Wilms tumor 
To investigate the cell origin of Wilms tumors in mouse, we used progenitor-specific Cre 
and the Cre-Loxp system to mosaically and somatically introduce genetic lesions into 
stromal progenitors or nephron progenitors. The genes we genetically engineered are 
commonly found mutated in human Wilms tumors, such as Wt1, Igf2 and β-catenin 
(reviewed in (Huff, 2007)). Based on the strong association of mutations in each of these 
genes found in human Wilms tumors, we combined the genetic mutations into different 
groups in our mouse models: Wt1 ablation with Igf2 up-regulation (Wt1-Igf2), β-catenin 
stabilization with (Wt1-/fl-β-catS) or without Wt1 ablation (Wt1+/fl-β-catS), and β-catenin 
stabilization only (β-catS). 
We found that the nephron progenitors but not the stromal progenitors were susceptible 
to Wilms tumor development. With the stromal progenitors targeted by Foxd1GCE, none of 
the combinations of mutations, F-Wt1-Igf2, F-Wt1-/fl-β-catS or F-Wt1+/fl-β-catS, resulted in 
Wilms tumors in the mutant mice (Table 3).  
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Designation Genotype Tamoxifen (mg/40gBW) 
Tumor mice / 
Mutant mice 
F-Wt1-Igf2 Foxd1GCE, Wt1-/fl, H19+/-m 3 at E11.5 0 / 9 
F-Wt1-/fl-β-catS Foxd1GCE, Wt1-/fl, β-cate3+/fl 3 at E11.5 0 / 17 
F-Wt1+/fl-β-catS Foxd1GCE, Wt1+/fl, β-cate3+/fl 3 at E11.5 0 / 11 
S-Wt1-Igf2 Six2GCE, Wt1-/fl, H19+/-m 1 at E11.5 0 / 27 
S-Wt1-/fl-β-catS Six2GCE, Wt1-/fl, β-cate3+/fl 3 at E14.5 8 / 11 
Six2GCE, Wt1+/fl, β-cate3+/fl 3 at E14.5 6 / 12 S-Wt1+/fl-β-catS 
S-β-catS Six2GCE, β-cate3+/fl 3 at E14.5 2 / 5 
C-Wt1-Igf2 Cited1Cre, Wt1-/fl, H19+/-m 1 at E14.5 9 / 18 
C-Wt1-/fl-β-catS Cited1Cre, Wt1-/fl, β-cate3+/fl 0.5 at E17.5 9 / 20 
C-Wt1+/fl-β-catS Cited1Cre, Wt1+/fl, β-cate3+/fl 0.5 at E17.5 3 / 7 
Table 3. Summary of mutant mouse cohorts 
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3.5  Nephron progenitors targeted with Wt1-β-cats mutations by Cited1Cre or Six2GCE 
gave rise to Wilms tumors 
In contrast to the stromal progenitors, nephron progenitors (Six2GCE or Cited1Cre), 
targeted with β-CATENIN stabilization with (S/C-Wt1-/fl-β-catS) or without Wt1 ablation (S/C-
Wt1+/fl-β-catS) led to the development of Wilms tumors in mice (Table 3). A small cohort of 
mice with β-CATENIN stabilization only (β-catS) by Six2GCE (S-β-catS) was also generated 
and the mutant mice also developed Wilms tumors (Table 3). Both unilateral and bilateral 
tumors were observed and the tumors were frequently associated with kidney cysts filled 
with blood fluid (Fig. 3.5 A-a & b). The S/C-Wt1-/fl-β-catS and S/C-Wt1+/fl-β-catS mutant 
cohorts had a significantly decreased survival compared to the control mice (Fig. 3.5 B and 
C). The Wt1-/fl-β-catS mutants showed a slightly reduced overall life span compared to the 
Wt1+/fl-β-catS mutants, but there was no significant difference (Fig. 3.5 B and C).  
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Figure 3.5 Development of WT from nephron progenitors.  
(A) Gross appearance of tumors from Six2GCE mutants (a), Cited1Cre mutants 
(b and c) of the indicated genotypes. (B and C) Kaplan-Meier tumor-free 
survival curve showing the incidence of mouse WTs in Six2GCE and Cited1Cre 
mutant mice with β-catenin stabilization with and without Wt1 ablation (S-Wt1-
/fl--cats, S-Wt1+/fl- -cats, C-Wt1-/fl- -cats, and C-Wt1+/fl- -cats) and Wt1 
ablation and IGF2 upregulation (C-Wt1-Igf2) in comparison to control mice.  
C-Wt1--catS 
To confirm that the tumors carried the mutations due to somatic recombination of the 
floxed allele(s) the mice carried, we examined the recombination status of the floxed alleles 
of β-catenin (β-catex3fl to β-catex3∆) and Wt1 (Wt1fl to Wt1∆) in tumors. PCR analysis detected 
the recombined β-catex3∆ in all S/C-Wt1-/fl-β-catS, S/C-Wt1+/fl-β-catS and S-β-catS tumors (Fig. 
3.6A). Interestingly, 50% of the tumors from S/C-Wt1-/fl-β-catS and S/C-Wt1+/fl-β-catS mice 
had incomplete recombination of the Wt1fl to Wt1∆ allele (Fig. 3.6B). These results and the 
observation of tumor development in S-β-catS tumors with wild-type Wt1 (Wt1+/+) suggested 
that β-CATENIN stabilization in nephron progenitors was sufficient to generate tumors and 
that Wt1 ablation was not required for the development of mouse Wilms tumors once β-
catenin was stabilized. β-catS tumors with or without Wt1 ablation (Wt1-/∆, Wt1-/fl, Wt1+/∆, 
Wt1+/fl and Wt1+/+) showed very similar phenotypes, histology and gene expression profile as 
shown below, therefore Wt1 dosage did not seem to play a role in the tumor development if 
β-CATENIN was stabilized. So we collectively designated the S-Wt1-/fl-β-catS and S-Wt1+/fl-
β-catS tumors as S-Wt1-β-catS tumors, and the C-Wt1-/fl-β-catS and C-Wt1+/fl-β-catS tumors 
as C-Wt1-β-catS tumors.  
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Figure 3.6 PCR detection of -catex3Δ andWt1Δ in tumors 
 
PCR analysis confirming the presence of gene mutations of the -catex3Δ in 
S/C-Wt1-/fl-β-catS and S/C-Wt1+/fl-β-catS tumors, and the Wt1Δ in C-Wt1-Igf2 
tumors. (A) PCR analysis of DNA from tumors for -catenin wild type or 
floxed allele, and exon3 deleted allele (-catex3+ or -catex3fl, & -catex3Δ). (B) 
PCR analysis of DNA from tumors showing Wt1fl and Wt1Δ.  
S-Wt1-/fl--catS 
-catex3+ or fl 
-catex3Δ 
T1 T1 T1 T2 T2 T2 
Tail 
A 
B 
S-Wt1+/fl--catS C-Wt1-/fl--catS 
T1 T2 T1 T2 
C-Wt1-/fl-Igf2 Normal 
Kidney T1 T1 T2 T2 
Wt1fl 
Wt1Δ 
S-Wt1-/fl--catS S-Wt1+/fl--catS C-Wt1-/fl--catS 
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3.6 Nephron progenitors targeted with Wt1-Igf2 mutations by Cited1Cre but not by 
Six2GCE generated Wilms tumors 
Although Six2GCE targeted nephron progenitors and Cited1Cre targeted un-induced 
nephron progenitors, interestingly, the Six2GCE, Wt1-/fl, H19+/-m (S-Wt1-Igf2) mutants did not 
develop tumors but the Cited1Cre, Wt1-/fl, H19+/-m (C-Wt1-Igf2) mutants did (Table 3). The C-
Wt1-Igf2 mutants developed circumscribed unilateral tumors at the periphery of the kidney 
(Fig. 3.5 A-c). PCR analysis detected the recombined Wt1∆ in all C-Wt1-Igf2 tumors (Fig. 
3.6B). The C-Wt1-Igf2 mutant cohort had a significantly decreased survival compared to the 
control mice (Fig. 3.5 C). 
 
3.7 In nephron progenitors, different sets of mutations resulted in Wilms tumors with 
different histologies 
With the same set of genetic alterations in nephron progenitors targeted with different 
Cre alleles, S-Wt1-β-catS tumors and C-Wt1-β-catS tumors showed very similar histology 
(Fig. 3.7 C-F). These tumors presented with an epithelial histology, mainly composed of 
epithelial elements surrounded by blastemal and stromal elements (Fig. 3.7 A-F). In the 
tumors, the primitive epithelial cells formed rudimentary tubules (Fig. 3.7 A, C and E), and 
the more differentiated epithelial cells possessed well-formed tubular structures with 
cuboidal cells or tall columnar cells (Fig. 3.7 B, D and F). Many of the tubular structures had 
luminal esophilic material resembling protein casts. The S-β-catS tumors with wild-type Wt1 
also had a very similar histology to S-Wt1-β-catS and C-Wt1-β-catS tumors with varying 
degree of Wt1 gene dosage (Fig. 3.7 A-F). 
By contrast, with the same nephron progenitor cell origin as S/C-Wt1-β-catS tumors, the 
C-Wt1-Igf2 tumors were characterized by a triphasic histology comprised of undifferentiated 
blastemal nodules, differentiating epithelial tubules, and stromal cells as did the UbCre-Wt1-
Igf2 tumors in previously published model with a Ubiquitous Cre-ERTM (Fig. 3.7 G-H).  
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Figure 3.7 Histology of WTs from Six2GCE and Cited1Cre mutant mice.  
 
H&E staining of WT sections of S-β-catS, S-Wt1-β-catS, C-Wt1-β-catS, and C-
Wt1-Igf2 mice. The S-β-catS (A&B), S-Wt1-β-catS (C&D), and C-Wt1-β-catS 
(E&F) tumors had a very similar epithelial histology. Rosettes lack of nuclear 
concentration at the center were present in S-β-catS (A), S-Wt1-β-catS (C), and 
C-Wt1-β-catS (E) tumors.  Predominant tubules with cuboidal or columnar cells 
were present in S-β-catS (B), S-Wt1-β-cateS (D), C-Wt1-β-catS (F) tumors. By 
contrast, C-Wt1-Igf2 (G) tumors had a triphasic histology with blastema, 
epithelia and stromal elements. (H) Triphasic histology of UbCre-Wt1-Igf2 
tumors. Scale bars: 100 µm. 
C-Wt1-Igf2 
S-Wt1-β-CatS C-Wt1-β-CatS S-β-CatS 
G 
A C 
B D 
E 
F 
UbCre-Wt1-Igf2 
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3.8 S/C-Wt1-β-catS and C-Wt1-Igf2 mouse tumors were proliferative 
To characterize the proliferation profile of the tumors, Ki67 IHC staining was performed. 
The S-Wt1-β-catS, C-Wt1-β-catS and C-Wt1-Igf2 tumors displayed the tumors cells were 
actively proliferating as assessed by Ki67 staining. However, the S-Wt1-β-catS and C-Wt1-β-
catS tumors had proliferative cells mostly in their epithelial elements (Fig. 3.8) whereas the 
C-Wt1-Igf2 tumors had a high proportion of proliferative cells in the blastemal and epithelial 
elements and some in the stromal (Fig. 3.8).  
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C-Wt1-Igf2 
S-Wt1-β-CatS 
Control 
Figure 3.8 WTs from Six2GCE and Cited1Cre mutant mice were 
highly proliferative.  
 
Ki67 IHC staining of tumor sections from control , S-Wt1-β-catS, 
C-Wt1-β-catS, and C-Wt1-Igf2 tumors. Scale bars: 50 µm. 
C-Wt1-β-CatS 
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3.9 Wt1-β-catS and Wt1-Igf2 tumors showed different RNA expression of epithelial 
differentiation markers 
Different subsets of human Wilms tumors had various expression profiles of 
developmentally regulated genes (Gadd et al., 2012). One subset histologically and 
molecularly corresponded to a differentiated epithelial stage of renal mesenchyme, while 
certain other subsets showed a histology and gene expression profile arrested at an early 
stage of renal mesenchyme (Gadd et al., 2012). In our mouse models, the S/C-Wt1-β-catS 
tumors showed an epithelial histology whereas the C-Wt1-Igf2 tumors had a less 
differentiated blastemal predominant histology. Therefore to examine whether, with the 
same nephron progenitor cell origin (SIX2+ or CITED1+), S/C-Wt1-β-catS tumors and C-Wt1-
Igf2 tumors had different expression of developmentally regulated genes, we characterized 
the gene/protein expressions of various differentiation stage markers in the tumors with 
qRT-PCR and IHC assays. 
Detection of RNA expression in these tumors using qRT-PCR demonstrated that the 
S/C-Wt1-β-catS and S-β-catS tumors had very low expression of the early mesenchyme 
markers such as Eya1, Osr1, Hoxa11, and Pax2, which are essential for the function and 
survival of the undifferentiated metanephric mesenchyme (Fig. 3.9). Compared to the S/C-
Wt1-β-catS and S-β-catS tumors, C-Wt1-Igf2 tumors had a significantly higher expression of 
these markers at early stage of renal mesenchyme differentiation (Fig. 3.9).  
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Figure 3.9 Comparison of gene expression of early mesenchyme 
markers in WTs of Six2GCE and Cited1Cre mutant mice.  
 
qPCR analysis of intermediate mesenchyme and early metanephric 
mesenchyme markers in mouse tumors showed very low expression of 
these markers in S/C-Wt1-β-catS and S-β-catS  tumors, and a significant 
higher expression in C-Wt1-Igf2 tumors.  
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Intermediate epithelial differentiation markers were also analyzed, such as Wnt4 and 
CyclinD1, which are specifically expressed in the renal vesicle, and Jag1, a marker in 
proximal tubule epithelium which is more differentiated than the renal vesicle. The qRT-PCR 
results showed that the S/C-Wt1-β-catS and S-β-catS tumors had low expression of Wnt4 
and CyclinD1, while C-Wt1-Igf2 tumors had a significantly increased expression of these 
precursor epithelial markers (Fig. 3.10). The S/C-Wt1-β-catS and S-β-catS tumors had lower 
expression of Jag1 than C-Wt1-Igf2 tumors, but the difference was not statistically significant 
(Fig. 3.10). In contrast, there was no difference in the mRNA expression level of E-cadherin 
between S/C-Wt1-β-catS, S-β-catS and C-Wt1-Igf2 tumors (Fig. 3.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
Figure 3.10 Comparison of gene expression of epithelia precursor 
and epithelia markers in WTs of Six2GCE and Cited1Cre mutant mice.  
 
qPCR analysis showed that S/C-Wt1-β-catS and S-β-catS tumors had a 
low level of expression of markers in post-induction renal vesicle (Wnt4 
and CyclinD1) and proximal tubule (Jag1). By contrast, C-Wt1-Igf2 
tumors had a significant higher expression in Wnt4 and CyclinD1, 
increased but not significant higher expression of Jag1. There was no 
difference in RNA expression of terminal epithelial differentiation marker 
E-cadherin between these tumors. 
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3.10 Wt1-β-catS and Wt1-Igf2 tumors showed slightly increased expression of 
muscle differentiation genes when compared to expression in normal kidneys 
Histologic examination of human Wilms tumors with WT1 mutation have shown ectopic 
muscle elements in the tumors, and genes involved in muscle differentiation were found up-
regulated in Wilm tumors with Wt1 mutations or Wnt/β-catenin activation (Fukuzawa et al., 
2004). Therefore, we checked gene expression of the muscle differentiation markers in 
mouse tumors. qRT-PCR analysis showed that, compared to normal kidneys, the S/C-Wt1-
β-catS, S-β-catS and C-Wt1-Igf2 tumors had a slightly increased expression of myogenesis 
markers, eg. Titin and Actin-α1, but the differences were not significant (Fig. 3.11). 
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Figure 3.11 qPCR analysis of gene expression of muscle cell 
differentiation markers in WTs of Six2GCE and Cited1Cre mutant 
mice.  
 
The S/C-Wt1-β-catS, S-β-catS and C-Wt1-Igf2 tumors had a slightly 
higher expression of markers in myogenesis, Titin and Actin-α1, than 
the normal adult kidneys.  
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3.11 S/C-Wt1-β-catS and C-Wt1-Igf2 tumors showed different protein expression 
pattern of differentiation markers 
Examination of protein expression level and subcellular localization of lineage markers 
by IHC staining showed that the S-Wt1-β-catS and C-Wt1-β-catS tumors expressed nephron 
progenitor cell markers, Cited1 and Six2, in their epithelial elements (Fig. 3.12). These 
tumors also expressed Dlk1 in the epithelial cells and some stromal cells (Fig. 3.12). Dlk1 is 
a stem cell marker and is highly expressed in blastemal component in human Wilms tumors 
with myogenesis (Fukuzawa et al., 2005). However, the tumors did not express Pax2 which 
was robustly expressed in the undifferentiated metanephric mesenchyme (Fig. 3.12 and 
3.22). In the S-Wt1-β-catS and C-Wt1-β-catS tumors, very few epithelial cells expressed 
CYCLIND1, a protein specifically expressed in the renal vesicle (Fig. 3.13). However, the 
tumor epithelial cells expressed E-cadherin, a terminally differentiated epithelial marker (Fig. 
3.13). These results suggested that the S-Wt1-β-catS and C-Wt1-β-catS tumors preserved 
expression of nephron progenitor markers but also expressed markers of a later stage of 
epithelial differentiation. 
In comparison, C-Wt1-Igf2 tumors expressed progenitor makers, Cited1 and Six2, and 
mesenchyme markers, Dlk1 and Pax2, in the blastemal and epithelial cells (Fig. 3.12), and 
the epithelial precursor marker CyclinD1 in some of the epithelial components (Fig. 3.13). 
However, they did not express E-cadherin (Fig. 3.13). These results suggested that the C-
Wt1-Igf2 tumors were more mesenchymal than the S/C-Wt1-β-catS tumors and that they 
maintained the progenitor-like features of their tumor initiating cells. 
Altogether, although S/C-Wt1-β-catS tumors and C-Wt1-Igf2 tumors arose from the same 
cell origin of nephron progenitors, the different genetic lesions (Wt1-β-catS vs. Wt1-Igf2) in 
these mutant mice resulted in different types of tumors, with the S/C-Wt1-β-catS tumors 
more epithelially differentiated while the C-Wt1-Igf2 tumors display mesenchymal elements 
and less differentiated epithelial elements and high expression of the mesenchyme genes.  
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Six2 
Figure 3.12 Expression of nephron progenitor markers and mesenchyme markers of WTs 
from Six2GCE and Cited1Cre mutants. 
IHC staining of Cited1, Six2, Dlk1 and Pax2 on sections from normal kidneys, S-Wt1-β-catS tumors, 
C-Wt1-β-catS tumors and C-Wt1-Igf2 tumors. Scale bars: 100 µm. 
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Figure 3.13 Expression of epithelia, mesenchyme and cell matrix markers in WTs of Six2GCE and 
Cited1Cre mutant mice.  
IHC staining for CyclinD1, E-cadherin, Vimentin, and Collagen IV of sections from normal kidneys, S-
Wt1-β-catS tumors, C-Wt1-β-catS tumors and C-Wt1-Igf2 tumors. Scale bars: 100 µm. 
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3.12 Expression of human WT blastemal marker and cellular matrix markers in S/C-
Wt1-β-catS and C-Wt1-Igf2 tumors  
Vimentin expression is observed in the blatemal and stromal components of human 
Wilms tumors. Interestingly, the S-Wt1-β-catS and C-Wt1-β-catS tumors expressed Vimentin 
in tumor epithelial cells (Fig 3.13). The C-Wt1-Igf2 tumors expressed Vimentin in blastemal, 
epithelial and stromal components in a diffuse manner (Fig. 3.13). 
IHC staining of cellular matrix marker on tumor sections showed positive staining for 
COLLAGEN IV in the extracellular matrix of the stromal cells in the S-Wt1-β-catS tumors, C-
Wt1-β-catS tumors and C-Wt1-Igf2 tumors (Fig. 3.13).  
 
3.13 β-catenin signaling and Wt1 target gene expression in mouse tumors 
In the mutant mice, β-catenin stabilization or Wt1 ablation was introduced. To determine 
whether their downstream signaling or expression of target genes was affected by the 
genetic alterations, we examined the activity of the Wnt/β-catenin pathway and the 
expression of Wt1 transcriptional targets in the mouse tumors.  
 
3.13.1 Nuclear accumulation of β-CATENIN protein in S/C-Wt1-β-catS tumors and 
increased cytoplasmic expression of β-CATENIN in C-Wt1-Igf2 tumors 
IHC staining of β-CATENIN showed that the S/C-Wt1-β-catS tumors and the C-Wt1-Igf2 
tumors had dramatically increased expression of β-CATENIN protein when compared to 
normal kidneys (Fig. 3.14). The S/C-Wt1-β-catS tumors showed a high level of β-CATENIN 
expression in the epithelial elements, and a large portion of these cells had β-CATENIN 
nuclear accumulation, confirming the stabilization of β-CATENIN in the β-catS tumor cells 
(Fig. 3.14). In comparison, β-CATENIN was expressed mainly in the cytoplasm of blastemal, 
epithelial and stromal components in the C-Wt1-Igf2 tumors (Fig. 3.14). 
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S-(Wt1)-β-CatS C-Wt1-β-CatS 
Figure 3.14 β-catenin signaling activity in WTs from Six2GCE and Cited1Cre mutant mice.  
 
IHC staining of β-catenin and downstream target C-myc of sections from normal kidneys, S-Wt1-β-catS 
tumors, C-Wt1-β-catS tumors and C-Wt1-Igf2 tumors. Scale bars: 100 µm. 
6
9
 
3.13.2 WNT/β-CATENIN signaling in mouse tumors 
The RNA of β-CATENIN direct target Axin2 was expressed in both S/C-Wt1-β-catS 
tumors and C-Wt1-Igf2 tumors, compared to the very low expression of Axin2 in control 
kidneys. The S/C-Wt1-β-catS tumors showed a slightly higher expression of Axin2 than the 
C-Wt1-Igf2 tumors (Fig. 3.15). This result is in agreement with the stabilization and nuclear 
accumulation of β-CATENIN protein in S/C-Wt1-β-catS tumors (Fig. 3.14). WNT/β-CATENIN 
inhibitor Wif1 was also elevated in S/C-Wt1-β-catS tumors and C-Wt1-Igf2 tumors compared 
to control kidneys (Fig. 3.15). The S/C-Wt1-β-catS tumors, however, had a much higher 
expression of Wif1 than did the C-Wt1-Igf2 tumors, suggesting a negative feedback loop 
responding to the stabilized β-CATENIN. Therefore, both S/C-Wt1-β-catS and C-Wt1-Igf2 
tumors displayed increased WNT/β-CATENIN activity, but the activity was higher in S/C-
Wt1-β-catS tumors than C-Wt1-Igf2 tumors. However, S/C-Wt1-β-catS tumors had low 
expression of other canonical targets of the β-CATENIN pathway, e.g., protein expression of 
C-MYC and transcription of Cxxc4 (Fig. 3.14 & 3.15). Thus, we propose that β-CATENIN 
signaling promotes tumor growth through different sets of targets or acts through non-
canonical cell-cell adhesion pathways.  
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Figure 3.15 qPCR analysis of β-Catenin signaling and Wt1 target 
expression in WTs from Six2GCE and Cited1Cre mutant mice.  
 
qPCR results showed that compared to normal kidneys, β-catenin 
pathway targets Axin2 and Cyclin E1 and Wnt/β-catenin inhibitors Wif1 
were increased in S-Wt1-β-catS tumors, and Wt1 targets CXXC4 and 
Cyclin E1 were upregulated in C-Wt1-Igf2 tumors.  
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3.13.3 Wt1 targets in mouse tumors 
Cyclin E is a target of β-catenin transcriptional activation and Wt1 transcriptional 
repression (Loeb et al., 2002). RNA expression of Cyclin E was increased in S/C-Wt1-β-catS 
tumors and C-Wt1-Igf2 tumors compared to control kidneys (Fig. 3.15). CXXC4 upregulation 
was found in WT1 mutated human Wilms tumors (unpublished data in our lab). We therefore 
measured the transcription of Cxxc4 and observed that Cxxc4 was significantly increased in 
C-Wt1-Igf2 tumors in comparison to S/C-Wt1-β-catS tumors and control kidneys (Fig. 3.15).  
 
3.14 S/C-Wt1-β-catS and C-Wt1-Igf2 tumors did not have increased pERK and pAKT 
expression 
The MAPK/ERK signal transduction pathway has been shown to be activated in mouse 
Wilms tumor models (Clark et al., 2011; Hu et al., 2010). To test whether this pathway was 
altered in our mouse tumors, we performed IHC staining of the effectors in MAPK/ERK 
signaling. However, we did not detect positive staining for pERK and pAKT in S/C-Wt1-β-
catS tumors and C-Wt1-Igf2 tumors by IHC (Fig. 3.16). 
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Figure 3.16 Expression of pERK and pAKT in WTs from Six2GCE and Cited1Cre mutant mice.  
 
IHC staining of sections from normal kidneys, S-Wt1-β-catS tumors, C-Wt1-β-catS tumors and C-
Wt1-Igf2 tumors showed negative staining of pERK and pAKT in tumors. Scale bars: 100 µm. 
Control C-Wt1-Igf2 S-Wt1-β-CatS C-Wt1-β-CatS 
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3.15 Proteomic analysis of S/C-Wt1-β-catS and C-Wt1-Igf2 tumors 
To identify cancer cell signaling pathways dysregulated in S/C-Wt1-β-catS and C-Wt1-
Igf2 tumors and pathways contributing to the differences in the differentiation status between 
S/C-Wt1-β-catS and C-Wt1-Igf2 tumors, we carried out RPPA analysis. RPPA is a high-
throughput proteomic assay which employs probing of a protein array with a panel of 
antibodies. The results of this assay demonstrated that the S-Wt1-β-catS tumors, the C-Wt1-
β-catS tumors and the C-Wt1-Igf2 tumors had a very similar protein expression profile (Fig. 
3.17). Tumors targeted by Six2GCE and Cited1Cre were therefore similar in their protein 
expression, and β-catS tumors with differential gene dose of Wt1 were also very similar in 
their protein expression. 
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Figure 3.17 Heat map of the results of RPPA analysis of gene 
expression among mouse Wilms tumors. 
Clustering with proteins differing among the groups from RPPA analysis 
showed similar protein expressions among mouse tumors. Cwb, C-Wt1-/fl-β-
catS tumors; cwH, C-Wt1-Igf2 tumors; sb, S-Wt1-/fl-β-catS tumors; swb, S-
Wt1+/fl-β-catS tumors; Wt1NB, control new born kidneys. 
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3.16 Correlation of mouse S/C-Wt1-β-catS and C-Wt1-Igf2 tumors to human WT 
subsets by gene expression analysis 
A previous study has identified different subsets of human Wilms tumors by global gene 
expression profile (Gadd et al., 2012). Subset 1 (S1) was identified as epithelial predominant 
tumors with gene expression signatures correlated with late differentiation stage, while 
Subset 2-5 (S2-5) showed a signature of gene expression associated with early 
metanephric mesenchyme and a triphasic histology (Gadd et al., 2012). The differences in 
histology and gene expression between S1 and S2-5 were very similar to that between the 
mouse S/C-Wt1-β-catS and C-Wt1-Igf2 tumors. Therefore, to find out whether S/C-Wt1-β-
catS tumors expressed genes whose expression characterized S1 tumors and whether C-
Wt1-Igf2 tumors expressed genes whose expression characterized a certain subset among 
subsets S2-5 tumors, we examined the gene expression pattern in mouse tumors with 
selected genes that differentiated the S1 and S2-5 subsets. The qRT-PCR analysis 
demonstrated a similar pattern in expression of some genes assessed between human 
subsets and our mouse models. For example, the expression of genes Hoxa11, HMGA2 
and Dlk1 were lower in S/C-Wt1-β-catS tumors than C-Wt1-Igf2 tumors and also were lower 
in S1 than S2-5 (Fig. 3.18). The expression of other selected genes, however, did not show 
a clear correlation of the mouse tumors to human subsets (Fig. 3.18). Here we were limited 
by the numbers of genes tested and the methods used. Global gene expression analysis 
with micro-array and cross-species comparison and clustering approach are needed to 
explore the relationships between the mouse tumor models and patient tumor subsets. 
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Figure 3.18 Analysis of possible correlation between mouse tumors to human WT subsets. 
qRT-PCR analysis of S/C-Wt1-β-catS and C-Wt1-Igf2 tumors with genes differentiating human WT subsets. 
Images are from Gadd, S., Huff, V., Huang, C.C., Ruteshouser, E.C., Dome, J.S., Grundy, P.E., Breslow, N., Jennings, L., Green, D.M., Beckwith, J.B., et al. (2012). 
Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study. Neoplasia 14, 
742-756. 
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Part II: Wt1 function in kidney progenitors during development 
Wt1 mutations predispose to Wilms tumor development, but the mechanisms by which 
Wt1 mutations in the undifferentiated mesenchyme contribute to the cell transformation have 
still not been identified. Therefore, we investigated the in vivo function of Wt1 specifically in 
kidney stromal and nephron progenitors by somatically deleting Wt1 early during kidney 
development.  
 
3.17 Wt1 ablation in stromal progenitors did not affect kidney development 
During kidney development, WT1 is expressed in the stromal progenitors and nephron 
progenitors in the undifferentiated metanephric mesenchyme (MM). It plays a critical role in 
cell survival and apoptosis of MM and MET during kidney development. With the progenitor-
specific Cre to conditionally delete Wt1, we could test the biological functions of Wt1 in each 
progenitor cell population. We applied a high dose of tamoxifen (6 mg/40 g bw) 
intraperitoneally to pregnant mice at E11.5 to ablate Wt1 in a high proportion of progenitors 
(Foxd1+ or Six2+).  
The Foxd1GCE/+, Wt1 -/fl (F-Wt1) kidneys with Wt1 ablation in stromal progenitors were 
examined at E19.5 and did not show a difference in morphology and histology compared to 
the controls (Fig. 3.19). The H&E staining showed that the mutant kidneys had the normal 
formation of mature nephrons, collecting ducts and stromal cells as in control kidneys (Fig. 
3.19). IHC with WT1 staining showed that the F-Wt1 mutant kidneys had normal 
development of metanephric mesenchyme, renal vesicles, comma-shaped bodies, S-
shaped bodies and glomeruli, similar to that observed in control kidneys (Fig. 3.19).  
To confirm that Wt1 ablation did not affect the differentiation and function of stromal 
progenitors, we used β-gal as a reporter to track the Wt1-ablated progeny cells derived from 
stromal progenitors (Foxd1GCE/+, Wt1 -/fl, R26βgal/+). β-gal staining of mutant kidneys in E19.5 
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and 3.5 month-old mice showed that the Wt1 ablated descendent cells from stromal 
progenitors retained stromal cell fates and differentiated normally into the interstitial cells, 
mesangial cells, pericytes and smooth muscle cells (Fig. 3.20). These results suggested that 
Wt1 in stromal progenitors does not seem to play a critical role on nephrogenesis. 
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F-Wt1 Control 
Figure 3.19 Wt1 ablation in stromal progenitors (Foxd1+) did not 
affect kidney development. 
 
H&E and Wt1 IHC staining of kidney sections at E19.5 showed that the 
mutant F-Wt1 kidneys had normal histology and nephrogenisis shown by 
Wt1 positively stained normal metanephric mesenchyme, renal vesicle, 
comma-shaped body, S-shaped body and glomeruli as the control. Scale 
bars: 200 µm. 
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Figure 3.20 stromal progenitors with Wt1 ablation showed normal cell 
differentiation. 
 
β-gal staining of kidney sections from E19.5 and 3.5 months old F-Wt1 
mutants showed that the β-gal labelled mutant cells differentiated normally 
into interstitial cells (i), mesangial cells (m), pericytes (p) and smooth 
muscle cells (sm). Scale bars: 100 µm. 
E19.5 
3.5 months old 
i 
i 
p 
m 
p 
m sm 
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3.18 Wt1 ablation in nephron progenitors resulted in defects in nephrogenesis 
In contrast, early Wt1 ablation at E11.5 in the nephron progenitors disrupted 
nephrogenesis. Histological examination showed that Six2GCE/+, Wt1 -/fl (S-Wt1) mutant 
kidneys at E19.5 had an expanded nephrogenic zone (NZ) where the progenitors resided, 
reduced nephron formation, and increased number of stromal cells surrounding the 
epithelial structures, compared to the control kidneys (Fig. 3.21). In the control kidneys, the 
metanephric mesenchyme condenses to the cap mesenchyme (CM) around the tips of 
ureteric buds and the mesenchyme differentiates upon induction by the ureteric buds. The 
ureteric buds are usually surrounded by 2-3 layers of CM cells (CITED1+, WT1+ and 
PAX2+). However, when Wt1 was ablated in the nephron progenitors, there were increased 
layers of CM cells (3-5 layers) around the ureteric buds in S-Wt1 mutants (Fig. 3.21 and 
3.22). The cells in the expanded NZ remained proliferative (Ki67+) and maintained the 
expression of nephron progenitor cell marker CITED1 and metanephric mesenchyme 
marker PAX2 (Fig. 3.22), suggesting that the accumulated CM cells retained their progenitor 
cell features. IF staining of WT1 showed that the S-Wt1 kidneys had marked reduction of 
comma-shaped bodies, S-shaped bodies and glomeruli (Fig. 3.23). IF staining of E-
CADHERIN also showed the decreased formation of epithelial structures in the S-Wt1 
kidneys (Fig. 3.23). Moreover, the ureteric buds (DBA+) were slightly dilated in the S-Wt1 
kidneys, compared to the control (Fig. 3.23). 
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Figure 3.21 Wt1 ablation in nephron progenitors resulted in the 
mesenchyme expansion and reduced nephrogenesis.  
 
H&E staining of kidney sections at E19.5 showed that the mutant kidneys 
had an expanded nephrogenic zone (depth indicated by red arrows) and 
decreased formation of nephrons, compared to the control kidneys. Scale 
bars: 200 µm. 
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Figure 3.22 Nephron progenitors with Wt1 ablation remained 
proliferative and maintained progenitor marker expressions. 
 
IF staining of kidney sections at E19.5 with proliferation marker Ki67 and 
progenitor markers Cited1 and Pax2. With Wt1 ablation, nephron progenitors 
in the expanded NZ were Ki67 positive and maintained the expression of 
Cited1 and Pax2. Pax2 was expressed in both progenitors and ureteric bud, 
so DBA was used here as a ureteric bud marker to indicate the Pax2+DBA- 
cap mesenchyme cells. Scale bars: 200 µm. 
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Figure 3.23 Wt1 ablation in nephron progenitors resulted in 
decreased epithelial differentiation. 
 
IF staining of kidney sections at E19.5 showing that the S-Wt1 mutant 
kidneys had a remarkable decrease in Wt1expressing comma-shaped 
bodies, S-shaped bodies and glomeruli. E-cadherin staining confirmed 
the reduced formation of epithelial structures caused by Wt1 ablation in 
nephron progenitors. DBA staining showing that the ureteric buds were 
slightly dilated in mutant kidneys compared to the control. (Arrow heads 
point to epithelial structures) Scale bars: 200 µm. 
Control 
S-Wt1 
E-cadherin / DBA Wt1 / DBA 
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To check whether the phenotype observed in S-Wt1 kidneys at E19.5 was evident at an 
earlier stage, we examined kidneys at E15.5. S-Wt1 kidneys at E15.5 also showed an 
expansion of the NZ (Fig. 3.24). In the expanded NZ, there were increased cells in the CM 
(Fig. 3.24). Cells in the NZ of S-Wt1 kidneys were proliferative (Ki67+) and expressed 
CITED1 as shown by IHC staining (Fig. 3.25). Compared to control kidneys, the S-Wt1 
kidneys showed decreased formation of K-CADHERIN expressing early epithelial structures 
such as renal vesicle, comma-shaped bodies and S-shaped bodies (Fig. 3.25).  
In all, these results suggested that Wt1 ablation in the nephron progenitors prevented 
cells from differentiating but these cells maintained their progenitor cell state in terms of 
proliferation and expression the nephron progenitor markers. 
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Figure 3.24 S-Wt1 mutants showed defects in nephrogenesis as 
early as at E15.5. 
 
H&E staining of kidney sections from controls and S-Wt1 mutants at 
E15.5. The phenotypes of expanded NZ and disturbed epithelial 
differentiation were observed as early as E15.5 in mutant kidneys. Scale 
bars: 200 µm. 
Control 
S-Wt1 
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Figure 3.25 Marker expressions of S-Wt1 mutant kidneys at E15.5. 
 
Ki67 staining showed that in S-Wt1 kidneys the expanded NZ was proliferative. 
The cells in the expanded NZ expressed progenitor marker Cited1. Compared 
to the controls, the mutant kidneys had fewer K-cadherin expressing early 
epithelial structures (*) such as renal vesicle, comma-shaped body and S-
shaped body. Scale bars: 200 µm. 
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3.19 Lineage tracing of Wt1 ablated nephron progenitors in vivo 
To study the fate of Wt1-ablated nephron progenitors, we used β-gal or tdTomato as 
reporters to track the mutant cells in S-Wt1 kidneys (Six2GCE/+, Wt1-/fl, R26βgal/+ or Six2GCE/+, 
Wt1-/fl, R26tdTomato/+). β-gal staining of mutant kidneys at E15.5 and E19.5 showed that most 
of the CM cells were labeled with β-gal, which suggested that the Wt1 ablated progenitors 
retained their capacity for self-renewal. Moreover, β-gal was expressed in disorganized 
epithelial-like structures with closed lumen compared to normal tubule formation in the 
control kidneys (Fig. 3.26). This phenotype may result from abnormal differentiation of the 
Wt1 ablated progenitors and possibly disrupted polarization in the cells. Very interestingly, 
the mutant kidneys had a few β-gal+ cells present in the kidney stromal, which was not 
detected in the control kidneys (Fig. 3.26). Whether this is due to mislocation of Wt1 ablated 
cells in the stromal or a trans-differentiation of mutant cells from nephron progenitor cell 
origin to a stromal cell fate is not known. 
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Figure 3.26 β-gal reporter tracing of Wt1 ablated cells from nephron 
progenitor origin. 
 
β-gal was expressed in the self-renewing progenitors in CM, in abnormally 
differentiated epithelial structures with closed lumen, and rarely but aberrantly 
in the the kidney stromal  (arrow heads). Scale bars: 200 µm. 
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3.20 Tracing Wt1 ablated cells from nephron progenitors with tdTOMATO reporter 
To monitor the behavior of the cells from Wt1 ablated nephron progenitors in real-time, 
we used a kidney rudiment culture system to visualize the rudiment growth by imaging 
cultures every 30 minutes for 3-4 days to generate time-lapse movies. tdTOMATO reporter 
was used to track the mutant cells.  
Pregnant mice were injected with 6mg/40g BW tamoxifen at E11.5, then at E13.5 mutant 
kidneys Six2GCE/+, Wt1-/fl, R26tdTomato/+ (S-Wt1-tdTomato) and littermate controls Six2GCE/+, 
Wt1+/fl, R26tdTomato/+ (S-tdTomato with a wild type Wt1) were dissected out and cultured on 
filters with media supplied with tamoxifen so that the floxed allele of Wt1 and R26tdTomato 
were recombined in a very high efficiency. The rudiments were placed inside an incubator 
equipped with a fluorescent microscope. Live images and tdTOMATO fluorescence images 
of the whole kidney rudiment were taken during culture. 
Representative images at the 15th and 51st hours of the rudiment culture showed that 
the wild type rudiments expressed tdTOMATO reporter robustly in the CM and clusters of 
differentiating epithelial cells (Fig. 3.27). However, the mutant rudiment had extended and 
elongated CM and lacked formation of epithelial structures (Fig. 3.27). PCR of isolated 
tdTOMATO expressing cells showed highly efficient Wt1 ablation in tdTOMATO marked 
cells derived from nephron progenitors (Fig. 3.27). 
To confirm the phenotype of impaired epithelial differentiation of mutant nephron 
progenitors, we characterized the expression of epithelial markers in the rudiments 
harvested after 3-day culture with immunofluorescence staining (IF). IF staining showed 
WT1 was expressed in cap mesenchyme and epithelial clusters in the control kidneys, while 
in the mutant the WT1 expressing cap mesenchyme was expanded, and very few WT1 
expressing epithelial clusters were observed (Fig. 3.27). K-CADHERIN staining confirmed a 
remarkable decrease of epithelial structure formation in the mutant rudiments (Fig. 3.27).  
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Figure 3.27 Tracking and monitoring Wt1 ablated cells from Six2GCE 
with tdTomato reporter in kidney rudiment culture 
 
Live field images and tdTomato images of rudiments during culture. PCR of 
isolated tdTOMATO+ cells confirmed efficient Wt1 ablation in nephron 
progenitor derived cells. IF staining of Wt1 showed mutant cells in cap 
mesenchyme were arrested in the MET. K-cadherin staining of the cultured 
rudiments confirmed the impaired formation of K-cadherin expressing 
epithelial structures. 
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Mutant Control 
Cre 
Wt1fl 
Wt1Δ 
To examine whether ureteric bud branching was affected by the differentiation arrested 
mesenchyme with Wt1 ablation, we did IF staining of the rudiment with LAMININ, a ureteric 
bud marker. We calculated the branching efficiency based on how many branches 
developed from the trunk to the bud ends. Branching efficiency of the ureteric bud in the 
mutant (Six2GCE/+; Wt1-/fl) was slightly lower than the control with Wt1 haploinsufficiency 
(Six2GCE/+; Wt1+/fl) and the control of Wt1 wild type (Wt1+/fl) (p-value=0.03) (Fig. 3.28). 
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Figure 3.28 Mutant kidneys showed slightly decreased branching 
efficiency. 
 
Laminin staining was used to visualize and highlight the ureteric buds for the 
calculation of the branching efficiency. After 3 day culture with tamoxifen, the 
mutant kidneys showed slightly less efficient in ureteric bud branching and 
slight dilation at the tips of the ureteric buds. Quantification of the ureteric bud 
branching efficiency showed that the mutant was not significantly different 
from the control Six2GCE/+; Wt1+/fl with Wt1 haploinsufficiency, but was 
significantly less efficient in branching than the control Wt1+/fl with wild type 
Wt1. 
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3.21 Gene expression analysis of kidneys with Wt1 ablation in nephron progenitors 
To investigate what potential targets or signaling pathways were affected by WT1 loss of 
function in nephron progenitors, we performed qPCR analysis of the mutant and control 
kidneys at E19.5. Pregnant mice were injected with tamoxifen at E11.5 to ablate Wt1 with 
Six2GCE/+ at E11.5 and kidneys were dissected out and RNA isolated for qRT-PCR analysis. 
We tested genes which were identified as markers in human WTs, effectors in Wnt/β-
CATENIN canonical and non-canonical Ca2+ pathway, differentiation markers in early 
mesenchyme and stromal and epithelial differentiation (Fig. 3.29). Among all the genes 
tested, two genes showed significant increase in mRNA expression of the mutants 
compared to the control (Fig. 3.29): Axin2, a Wnt/β-CATENIN direct target, and, Osr1, an 
early mesenchyme marker (Fig. 3.29). These results suggested that Wt1 ablation in nephron 
progenitors resulted in increased the Wnt/β-CATENIN signaling, in agreement with a 
previous study that showed that Wt1 was a repressor for the Wnt/β-CATENIN pathway 
(Chang et al., 2008). The results of Osr1 up-regulation in S-Wt1 kidneys and the presence 
of S-Wt1 cells in kidney stromal suggested that Wt1 ablation in the nephron progenitors may 
help cells to acquire long-term self-renewal and differentiation plasticity to an earlier lineage, 
and potentially prepare the cells to be transformed to a tumor cell. 
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Figure 3.29 Gene expression analysis of S-Wt1 mutant kidneys and control kidneys at E19.5. 
 
qPCR analysis of the S-Wt1 mutant and control kidneys at E19.5 with genes in Human WTs, Wnt/β-Catenin 
canonical and non-canonical pathways and differentiation markers. 
Control: Six2GCE; Wt1+/fl 
Mutant: Six2GCE; Wt1-/fl 
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3.22 Wt1 ablation in nephron progenitors resulted in fibrosis in adult kidneys 
To assess the longer term effects of Wt1 ablation in nephron progenitors, we examined 
adult kidneys in 2 month-old mice. The mutant kidneys displayed a thinner cortex and 
multiple lesions with tubule dilation (Fig. 3.29). To check whether the cells in the lesion 
came from S-Wt1 mutant cells, we used β-gal to track the cells with Wt1 ablation. In the 
adult mutants, β-gal reporter was expressed in the tubule cells but not in the cells in the 
lesion (Fig. 3.30). This indicated that the lesions may not directly come from Wt1 ablated 
nephron progenitors, but they were caused by a secondary response to the Wt1 ablated 
cells. Alternatively, negative staining of β-gal in lesions could be due to technical difficulties 
in visualizing β-gal staining in lesional cells with little cytoplasm. The cells in the lesions 
were positive for Ki67 staining, suggesting they were proliferative (Fig. 3.30). To identify 
what type of cells constituted the lesions, we did IHC and IF staining with protein markers. 
The cells in these lesions did not express CITED1, SIX2 and K-CADHERIN (Fig. 3.30), 
which confirmed that these cells were not persisting nephron progenitor cells. To determine 
whether the lesion cells were inflammatory cells, we stained kidney sections with F4/80 
(macrophage marker) IF staining. The cells in the lesions were not F4/80 expressing 
macrophages (Fig. 3.31). However, these lesion cells were positively stained for VIMENTIN, 
suggesting a fibrotic nature of the lesions. PAS positive staining and extensive deposition of 
Type IV Collagen in the lesions in the mutant kidneys further confirmed that the lesions were 
fibrotic tissues (Fig. 3.31). Therefore, early Wt1 ablation in the nephron progenitors led to 
the formation of fibrosis in the adult kidneys, but it is not clear how the fibrotic tissues were 
formed. 
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Figure 3.30 Wt1 ablation in nephron progenitors results in lesion formation 
in adult kidneys 
 
H&E staining of kidney sections from S-Wt1 mutant and control kidneys at 2 
months old. Mutants showed a thinner cortex and lesion formation highlighted by 
red line. β-gal staining of kidney sections from S-Wt1-β-gal mutant kidneys 
showed that the lesions did not express β-gal. IHC staining of kidney sections 
showed that cells in the lesions did not express Six2, Cited1 and K-cadherin, but 
Ki67. Scale bars: 250 µm. 
Control  
Wt1+/fl; R26βgal/+ 
Mutant  
Six2GCE/+; Wt1-/fl; R26βgal/+ 
Mutant: Six2GCE/+; Wt1-/fl; R26βgal/+ 
H&E 
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Figure 3.31 Lesions in Wt1 ablated adult mutants were fibrotic. 
 
IF staining of adult kidney sections with macrophage marker F4/80 and fibrosis markers Vimentin, Collagen 
IV, and Masson’s Trichorme staining. Lesions in the mutants were negative for F4/80 staining but positively 
stained for Vimetnin, Masson’s Trichrome and Collagen IV. Scale bars: 200 µm. 
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Chapter 4: Discussion 
4.1 Cell origin of Wilms tumors in metanephric mesenchyme 
Wilms tumor is an embryonal tumor of the kidney. Typically it has a triphasic histology 
and is thought to be a malignancy derived from transformed fetal metanephric mesenchyme, 
which can variably differentiate and clonally expand to generate the bulk of the tumor. 
However, it is not clear yet what type(s) of cells in the undifferentiated metanephric 
mesenchyme are the origins of the tumors. Recent global expression analysis of a large 
panel of WT patients has identified different subsets of WTs that are distinct in their clinical 
outcomes and gene expression profiles. These subsets variably express specific genes that 
correspond to early renal mesenchyme or fully differentiated epithelium. These results 
suggest that different subsets of WTs may arise from cells transformed at different stages of 
differentiation and that the stage of differentiation at which a tumor arises is a major factor in 
determining tumor biology and clinical outcomes. 
To investigate the malignant potential of different types of cells in the undifferentiated 
metanephric mesenchyme, we generated cohorts of mice by using cell-type-specific 
tamoxifen-inducible Cre to somatically and mosaically introduce genetic lesions into specific 
progenitor cell populations including stromal progenitors (by Foxd1GCE) and nephron 
progenitors (by Six2GCE or Cited1Cre). The gene alterations introduced into the mice are 
frequently observed in tumors from WT patients and affect genes which are expressed in 
the metanephric mesenchyme and play essential roles in kidney development. Using the 
Cre-Loxp system, we somatically and mosaically ablated Wt1 in the background of Igf2 up-
regulation (Wt1-Igf2) or stabilized β-catenin with or without Wt1 ablation (Wt1-β-catenin).  
With the gene alterations we introduced, the nephron progenitors but not the stromal 
progenitors gave rise to Wilms tumors. During early kidney development, the stromal 
progenitors and nephron progenitors are derived from the OSR1+ cells in the metanephros 
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and the stromal progenitors and nephron progenitors are fated exclusively (Mugford et al., 
2008b). Based on previous findings that tumor cells retain features of progenitor cellular 
origin in brain tumors (Schuller et al., 2008), we initially speculated that targeting the stromal 
progenitor would result in the stromal predominant type of Wilms tumors, whereas targeting 
the nephron progenitor would lead to the blastemal or epithelial predominant type of Wilms 
tumors. We found that targeting the stromal progenitors with either group of gene mutations, 
Wt1-Igf2 or Wt1-β-catenin, did not lead to Wilms tumors, suggesting that the stromal 
progenitors were refractory to the oncogenic stimulation of Wt1-Igf2 or Wt1-β-catenin 
genetic alterations. However, both combinations of gene alterations introduced into the 
nephron progenitors resulted in Wilms tumor development, suggesting that the nephron 
progenitors are the tumor initiating cells. Moreover, the transformed nephron progenitors 
were able to aberrantly differentiate to the different cell types in the tumors such as 
blastemal, epithelial, and stromal elements. Altogether, the stromal progenitors and nephron 
progenitors with different lineages showed different tumorigenic potentials. This was also the 
case in studies of the cell origin of pediatric brain tumors, in which different progenitors 
exhibited different susceptibility for tumor transformation and progenitors with different 
lineage commitments generated different types of tumors (Swartling et al., 2012). As 
development proceeds, progenitors exit the cell cycle and differentiate; however, with 
oncogenic stimulation, progenitors acquire the ability to self-renew long-term and remain 
proliferative and eventually comprise the bulk of tumors (Yang et al., 2008). The Patched 
deletion medulloblastoma model also suggested that the granule lineage is specifically 
sensitive to the oncogenic stress of hedgehog signaling, though the multipotent neural stem 
cells were targeted (Yang et al., 2008). 
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4.2 Stromal progenitors are not at risk of Wilms tumor development 
One possible reason for the absence of tumor development from the stromal progenitor 
is the intrinsic property of the progenitor itself. Transcriptionally and epigenetically, the 
stromal progenitors and nephron progenitors are programmed differently. When stromal 
progenitors were targeted with genetic lesions, they may undergo apoptosis or may function 
normally with the mutations. We did not test in this study whether stromal progenitors with 
mutations underwent apoptosis. However, the resistance of stromal progenitors to 
oncogenic stimulation is consistent with our observation from the developmental study that 
when stromal progenitors were targeted with Wt1 ablation only, stromal progenitor-derived 
cells differentiated normally and kidneys appeared normal. When β-catenin was deleted in 
stromal progenitors by using constitutive Foxd1-Cre, the phenotype of the stromal progenitor 
derived cells, nephron induction and ureteric bud branching, was normal except for a slightly 
thicker cortex and lack of medulla development (Yu et al., 2009). Therefore, although WT1 
and β-CATENIN are expressed in the stromal progenitors, normal expression of these 
genes may not be important for the stromal progenitors to survive, self-renew, proliferate 
and differentiate. In other words, the stromal progenitors are not sensitive to the genetic 
manipulations we used here for transformation. More work is required to test whether 
additional gene mutations, for example p53 mutations, are needed for cell transformation of 
the stromal progenitors. On the other hand, the microenvironment of the tumor initiating cells 
is also critical for tumor development. The niche of the stromal progenitor, resulting from the 
local paracrine signaling, extracellular cell matrix, angiogenesis and inflammatory cells, may 
not favor cell transformation. 
 
4.3 Nephron progenitors are competent to generate Wilms tumors 
Gene expression and IHC analysis of human Wilms tumors showed that tumors had a 
profile of marker gene expression similar to that of the nephron lineage, including 
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expression of SIX2, CITED1 (Murphy et al., 2012), PAX2 and PAX8 (Eccles et al., 1995). 
This suggested that the nephron progenitor is a more promising target as the tumor initiating 
cell than the stromal progenitor. The genes we genetically engineered have been shown to 
be critical in functions of the nephron progenitors. Wt1 is essential for MET of the nephron 
progenitor, thus when Wt1 is ablated, the progenitor can not go through MET but maintains 
a progenitor status of self-renewing and proliferating. When Igf2 is simultaneously over-
expressed, which promotes the metanephric mesenchymal cell to proliferate, the nephron 
progenitor becomes fully transformed. β-catenin regulates the nephron progenitors in cell 
survival, self-renewal, proliferation and differentiation (Schmidt-Ott and Barasch, 2008). 
When the balances between these functions are disrupted by β-CATENIN stabilization, the 
nephron progenitor cells are transformed. However, we can not rule out the possibility that 
the nephron progenitor cells are partially transformed when they are targeted with the 
genetic alterations and that the mutated cells persist. They become completely tumorigenic 
until a later stage when they gain further epigenetic alterations or when they are affected by 
microenvironment changes. 
 
4.4 Wilms tumors with the nephron progenitor origin targeted with Six2GCE or Cited1Cre 
We targeted the nephron progenitor by using two Cre lines, Six2GCE and Cited1Cre. 
CITED1 is expressed in the uninduced nephron progenitor that has the capability of self-
renewal and resistance to differentiation. SIX2 is expressed in the uninduced nephron 
progenitor and also the induced nephron progenitor that responds to WNT9b-β-CATENIN 
signaling and starts to undergo MET. A subset of SIX2-expressing cells also expresses 
CITED1. Both Cited1 and Six2 are markers for the multipotent and self-renewing nephron 
progenitors, but Cited1 is not essential for nephrogenesis because Cited1 deletion in mice 
does not affect kidney development (Boyle et al., 2007). Six2 is required for the 
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maintenance of self-renewal of nephron progenitors (Self et al., 2006). We took advantage 
of the availability of Cited1Cre and Six2GCE mouse lines and incorporated a flox allele of the 
gene of interest to target mutations to the nephron progenitors.  
The difference between the Cited1Cre and Six2GCE Cres is that the Cited1Cre is a 
transgene while Cited1 and Six2 genes are wild type, whereas Six2GCE is a knock-in allele, 
resulting in Six2 is haploinsufficiency. When we targeted Wt1 ablation into the nephron 
progenitors with Cited1Cre (C-Wt1-Igf2), triphasic Wilms tumors developed, but tumors did 
not develop in S-Wt1-Igf2 mutants. The difference between the Cited1Cre+ cells and the 
Six2GCE+ cells is that they have different gene dosages of Six2. Six2 has been shown to be 
essential for the self-renewal of nephron progenitors (Kobayashi et al., 2008). Moreover, in 
human Wilms tumors, SIX2 is expressed in blastemal elements of tumors (Murphy et al., 
2012), and overexpression of SIX2 in a human Wilms tumor cell line enhanced cell survival, 
proliferation and migration of tumor cells (Pierce et al., 2014; Senanayake et al., 2013). 
Overexpression of Six2 repressed differentiation directed by Tcf/Lef dependent Wnt 
signaling and promoted the stemness facilitated by Survivin dependent Wnt signaling 
(Pierce et al., 2014). It is possible that in the genetic context of Wt1-Igf2, wild type Six2 
expression and Wt1 ablation synergistically contributed to cell transformation, and 
haploinsufficiency of Six2 in Six2GCE+ cells prevented cells from being tumorigenic. Thus, 
the Six2GCE+ cells were not as sensitive as the Cited1Cre+ cells were to the oncogenic effects 
of Wt1 ablation. 
However, both Cited1Cre+ cells and Six2GCE+ cells were able to give rise to Wilms tumors 
when β-CATENIN was stabilized. This indicates that in the case of β-CATENIN stabilization, 
Six2 gene dosage (Wild type in Cited1Cre+ cells or haploinsufficient in Six2GCE+ cells) did not 
affect the malignant competency of nephron progenitors. Moreover, phenotypically, 
molecularly, and immunohistochemically, tumors targeted by both Cre alleles, Cited1Cre or 
Six2GCE, are very similar. Both the Cited1Cre and Six2GCE tumors histologically showed a 
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primitive epithelial type of Wilms tumor and were associated with kidney cyst phenotype. 
qRT-PCR and IHC analysis showed the Cited1Cre and Six2GCE tumors had a similar 
expression profile of differentiation markers. The unsupervised clustering of RPPA results 
with Cited1Cre and Six2GCE tumors did not show a difference in the protein expression level of 
the oncoproteins and tumor suppressors in the canonical cancer signaling pathway that 
were included in the RPPA assay. Since both Cited1Cre and Six2GCE targeted the nephron 
progenitors, it is not surprising that they resulted in similar type of Wilms tumors.  
 
4.5 Wt1 is not required for tumor development once β-CATENIN is stabilized in 
nephron progenitors 
When β-CATENIN stabilization was targeted into the nephron progenitors with either 
Six2GCE or Cited1Cre, tumors developed, despite the fact that these tumor mice carried 
different genotypes of Wt1, eg. Wt1-/fl, Wt1+/fl, or Wt1+/+. Moreover, in nephron progenitors 
with β-catS, the Wt1 floxed allele was either completely or partially recombined, suggesting 
that Wt1 status is not relevant in tumorigenesis when β-catenin is stabilized in nephron 
progenitors. In particular, the mutant mice with Wt1+/+ developed tumors and all these 
tumors had β-catS, confirming that β-catenin stabilization is sufficient to transform nephron 
progenitors. Furthermore, qPCR, IHC and RPPA analysis of the tumors with differential 
gene dosage of Wt1 showed very similar histology and expression profiles of marker genes 
and cancer signaling proteins between these tumors. However, in human Wilms tumors, β-
CATENIN stabilization mutations are exclusively associated with WT1 loss of function 
mutations, and WT1 mutations and β-CATENIN mutations occurred in sequence during 
tumor progression (Maiti et al., 2000) (Fukuzawa et al., 2007). It is because of these findings 
that we initially designed the experiments by combining Wt1 ablation together with β-catenin 
stabilization and engineered them genetically into mouse embryo kidney cells. The different 
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roles of Wt1 in tumor development between mice and humans could be explained by the 
differences in the developmental process between mice and humans. 
 
4.6 Within the nephron progenitor cell origin, different genetic lesions generated 
different tumor types 
With the nephron progenitor cell origin, we found that different sets of mutations (Wt1-β-
catS and Wt1-Igf2) generated different types of Wilms tumors. Wt1-β-catS tumors and Wt1-
Igf2 tumors had a similar tumor onset, penetrance of tumor occurrence and tumor 
proliferation profile. But Wt1-Igf2 tumors did not have the cystic kidney phenotype that we 
observed in Wt1-β-catS tumors. Expression analysis of differentiation markers showed that 
Wt1-β-catS tumors were more epithelially differentiated, while the Wt1-Igf2 tumors were 
more mesenchymal. 
Wt1-β-catS tumors were characterized by a differentiated epithelial histology, composed 
mainly of epithelial cells forming tubule-like structures surrounded by stromal cells. These 
tumor epithelial cells expressed the epithelial differentiation marker E-CADHERIN, which 
was not expressed in the Wt1-Igf2 tumors. Interestingly, these epithelial tumor cells also 
showed expression of the nephron progenitor markers CITED1 and SIX2 and the 
mesenchymal stem cell marker DLK1, suggesting that these cells were abnormally 
differentiated and retained features of their progenitor cell origin. In addition, Wt1-β-catS 
tumors expressed muscle differentiation markers, suggesting that a muscle cell 
differentiation program was likely activated by β-CATENIN stabilization. However, they did 
not express intermediate mesenchyme markers (Eya1, Hoxa11 and Osr1), renal 
mesenchyme markers (Pax2 and NCAM) and precursor epithelial markers for renal vesicle 
(Wnt4, CyclinD1 and Jag1) as Wt1-Igf2 tumors did.  
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By contrast, Wt1-Igf2 tumors displayed a triphasic histology, comprised dominantly of 
undifferentiated blastemal cells, differentiated epithelial cells and stromal cells. Wt1-Igf2 
tumors showed high expression of genes upregulated in nephron progenitor (Cited1, Six2 
and Pax2) and in renal vesicle (Wnt4, CyclinD1 and Jag1). This expression profile correlates 
with the histology of blastemal and differentiating epithelial elements in the tumors. 
Moreover, genes corresponding to intermediate mesenchyme (Eya1, Hoxa11 and Osr1) 
were highly expressed in Wt1-Igf2 tumors. Overexpression of the transcription factors Six2, 
Eya1, Hoxa11, Osr1 and Snail2 in differentiated proximal tubule cells was sufficient to 
reprogram cells to nephron progenitor cells (Hendry et al., 2013). Thus, we propose that the 
transformed cells in Wt1-Igf2 tumors may have undergone dedifferentiation and acquired 
increased ability of self-renewal and multipotency. Furthermore, Wt1-Igf2 tumors showed 
elevated expression of genes involved in muscle differentiation such as Ttn and Actin-a1, 
demonstrating an enhanced plasticity in differentiation capabilities in tumor cells like in the 
intermediate mesenchyme. 
The molecular and immunohistochemical analysis of mouse tumors indicated that the 
differentiation program of the tumor-initiating cells was influenced by the genetic lesions of 
Wt1-Igf2 or Wt1-β-catenin, which is likely related to the functions of the genes in nephron 
progenitors for normal renal development. 
 
4.7 Gene mutations impact dominantly on the formation of different types of mouse 
WTs 
Wt1 and β-catenin are both critical in regulating the functions and differentiation of the 
nephron progenitors. When one or more of them are deregulated, the resulting signaling can 
become oncogenic and facilitate cell transformation, and at the same time, it can affect the 
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cell differentiation program by either directing cells to dedifferentiate or to differentiate 
ectopically.  
Wt1 is required for MET (Hu et al., 2010). Wt1 deletion prevented the nephron progenitor 
cells from differentiating, but preserved progenitor cells in a self-renewing and stem-like 
state. A very recent study found that at E11.5 and E15.5, at the periphery of the CM, there 
were rarely cells expressing both SIX2 and FOXD1 and that these few cells with dual 
identities could be fated toward either the stromal or epithelial cell types (Brunskill et al., 
2014). Therefore, it is possible that the Wt1-Igf2 mutant nephron progenitor cells could 
dedifferentiate to an earlier lineage such as the SIX2-FOXD1 dual identity state or even an 
earlier state, such as intermediate mesenchyme. In addition to the partial transformation 
resulting from Wt1 deletion, the Igf2 overexpression that promoted cell proliferation caused 
the progenitor cells to fully transform into tumor cells with a broad differentiation potential.  
Wnt/β-catenin signaling has been shown to be essential for nephron progenitors to 
survive, proliferate, and self-renew (Park et al., 2007). WNT9b signaling from the ureteric 
bud induces the undifferentiated and uninduced nephron progenitor cells to differentiate via 
activation of the canonical β-CATENIN signaling pathway (Schmidt-Ott and Barasch, 2008). 
However, when the cells further differentiate, β-CATENIN signaling activity must be reduced 
for full epithelialization (Kuure et al., 2007). Our study demonstrated that constant activation 
of β-catenin signaling was not only sufficient to transform nephron progenitor cells but also 
biased the tumorigenic cells towards epithelial differentiation, thus generating the primitive 
epithelial type of WTs. Moreover, we observed a strong association of kidney cyst formation 
with the epithelial tumors and we speculated that β-CATENIN stabilization may disrupt cell 
adhesion formation or cilia formation and increase the cytokinesis of the tumor cells. 
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4.8 Comparison of tumor models in this study and published mouse WT models 
The first Wilms tumor mouse model was generated by using a ubiquitous tamoxifen-
inducible Cre to somatically and mosaically ablate Wt1 together with systematic over-
expression of Igf2 (UbCre-Wt1-Igf2). In this model, about 64% of mutants developed tumors 
by the age of 19 weeks (Hu et al., 2010). The UbCre-Wt1-Igf2 tumors had triphasic histology 
and showed activated extracellular signal-regulated kinase (ERK) signaling. In our C-Wt1-
Igf2 mouse model targeted by Cited1Cre, the tumors developed at 70 weeks old with a 
frequency of 50% of the mutant mice. The C-Wt1-Igf2 tumors also had a triphasic histology 
similar to the UbCre-Wt1-Igf2 tumors. The differences in tumor latency between the UbCre-
Wt1-Igf2 mutants and the C-Wt1-Igf2 mutants may result from the different targeting 
strategies with Cre expression driven by different promoters. In the UbCre-Wt1-Igf2 model, 
kidney cells were targeted at E11.5. At E11.5, Wt1 is expressed in the metanephric 
mesenchyme mainly composed of the nephron progenitors, stromal progenitors, and 
possibly some other un-identified progenitor cell types (Mugford et al., 2009). Thus, all these 
cell types could serve as candidate targets for tumor cell transformation. However, in our C-
Wt1-Igf2 model, only the uninduced nephron progenitors were targeted at E14.5. We 
speculated that in the UbCre-Wt1-Igf2 model, a cell population at an earlier lineage than the 
nephron progenitor was targeted by the ubiquitous Cre. This stem cell population had a 
higher capacity of proliferation and self-renewal than the nephron progenitor and led to 
faster expansion of the transformed cells and thus an earlier tumor onset in UbCre-Wt1-Igf2 
mice. There was a higher content of blastemal cells and a lower content of epithelial cells in 
the histology of UbCre-Wt1-Igf2 tumors than that in the C-Wt1-Igf2 tumors. This observation 
may also reflect our speculated stem cell origin of the UbCre-Wt1-Igf2 tumors versus the 
lineage restricted nephron progenitor cell origin of the C-Wt1-Igf2 tumors. Cells targeted by 
the UbCre could include the CITED1+ nephron progenitors, so the tumor spectrum of UbCre-
Wt1-Igf2 tumors should include tumors like the C-Wt1-Igf2 tumors. Indeed, we observed that 
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some of the UbCre-Wt1-Igf2 tumors histologically appeared very similar to the C-Wt1-Igf2 
tumors.  
Later, another mouse model was reported in which mini-primitive epithelial WTs 
developed with the use of Cited1Cre to stabilize β-CATENIN with or without Kras activation 
postnatally (C-β-catS-Kras) (Clark et al., 2011). In this model, a proximal tubule specific γGT-
Cre was also used to stabilize β-CATENIN and activate Kras (γGTCre-β-catS-Kras) and the 
development of the same epithelial WTs was detected as was the case with the C-β-catS-
Kras tumors. The C-β-catS-Kras and γGTCre-β-catS-Kras tumors looked histologically very 
similar to our S/C-Wt1-β-catS and S-β-catS tumors. However, our mouse tumors had a cystic 
kidney phenotype that was absent in C-β-catS-Kras and γGTCre-β-catS-Kras tumors. In our 
mouse models, the Six2GCE or Cited1Cre was activated by tamoxifen at an early stage of 
kidney development (E14.5 or E17.5) to target the nephron progenitors, which was different 
from the C-β-catS-Kras and γGTCre-β-catS-Kras models where cells were targeted at the post-
natal stage, when CITED1+ nephron progenitor cells were depleted and γGT+ cells were fully 
differentiated. It was likely that the γGT+ tubule cells underwent dedifferentiation when they 
had β-catenin and Kras activation during the cell transformation process. Altogether, with β-
CATENIN stabilization, both multipotent nephron progenitors and completely differentiated 
proximal tubules presented the capacity to give rise to epithelial WTs, suggesting that similar 
type of WTs can be generated from diverse sources of cell origins. 
Very recently, overexpression of a heterochronic regulator Lin28 in primordial germ cells 
but not in nephron or stromal progenitors generated Wilms tumor (Urbach et al., 2014). This 
suggested that different types of cells at different lineages can serve the cell origins of WTs 
but that the malignant potentials depended on the context of the genetic alterations. 
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4.9 Comparison of tumor models with human WT subsets 
To correlate the mouse tumors with the identified 5 subsets of human WTs (Gadd et al., 
2012), we selected a few significant genes differentiating the human tumor subsets. We 
compared the expression patterns of these genes in the different mouse tumor types with 
the intent of determining whether these expression patterns were consistent with any of the 
human tumor subsets. 
S1 tumors are characterized by epithelial tubular differentiated histology without muscle 
differentiation. S1 tumors had low expression of genes in early metanephric mesenchyme 
but expressed genes in the post-induction stage of nephron and mature epithelium. S2-S5 
tumors showed triphasic histology with varying degree of skeletal muscle differentiation, and 
molecularly S2-S5 tumors were similar to one another. S2 tumors had loss of Wt1 
expression and Wnt activation, and genes enriched in S2 corresponded to the differentiation 
stage before mesenchyme induction (e.g. intermediate mesenchyme) and to kidney 
interstitium. Compared to S2 tumors, S3 also had low Wt1 expression, but the expression of 
skeletal muscle differentiation genes were lower and activity of canonical signaling such as 
Wnt, Tgfβ, NFAT and Ras pathways was lower. S4 tumors were also very similar to S2 
tumors in gene expression pattern, but showed less evidence of Wt1 loss of expression and 
Wnt activation. S5 tumors expressed genes corresponding to early metanephric 
mesenchyme.  
The epithelial histology of S/C-Wt1-β-catS and S-β-catS tumors were like the S1 tumors 
except that there are no β-catenin mutations in S1. However, the C-Wt1-Igf2 tumors showed 
triphasic histology, which mimicked S2-S5 tumors histologically. 
The genes that we checked in mouse tumors included genes in intermediate 
mesenchyme before nephron induction, muscle differentiation and Wnt signaling. The 
mesenchymal marker genes (Hoxa11, HMGA2 and Dlk1) that were expressed significantly 
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lower in β-catS mouse tumors than the C-Wt1-Igf2 tumors were also expressed lower in S1 
tumors than other subtypes. Therefore we thought that β-catS tumors may mimic S1 not only 
histologically but also in gene expression, and that C-Wt1-Igf2 tumors may correlate to 
certain subset among S1-S5.  For the genes involved in muscle differentiation such as Pitx2, 
Ttn and Actin-a1, the β-catS tumors and the C-Wt1-Igf2 tumors had similar expression level, 
which was also observed between S1, S3 and S5. S3 tumors had low expression of Wt1, 
less Wnt activation and high expression of Igf2, so we speculated that C-Wt1-Igf2 tumors 
could be more related to S3 tumors. For the expression of Wnt/β-catenin inhibitor Wif1, β-
catS tumors had higher expression than the Wt1-Igf2 tumors, which was not the case 
between S1 and the other subsets, probably due to the lack of β-catenin mutations in S1 
tumors. Together, based on these very preliminary data, we speculated that the β-catS 
tumors may correspond to S1, while C-Wt1-Igf2 tumors may be related to S3. However, 
further analysis such as microarray, cross-species comparison and clustering will be 
required to define the correlation between the mouse models and the human tumor subsets. 
 
4.10 Wt1 function in kidney development 
Functional mutations of WT1 have been found in 20% of Wilms tumor patients. To 
understand the mechanisms by which WT1 loss of function predisposes to malignant 
transformation, it is important to understand WT1 function in kidney development. Wt1 is 
expressed in the metanephric mesenchyme, mainly containing stromal and nephron 
progenitors at an early stage of kidney development. Therefore, we used a high dose of 
tamoxifen to ablate Wt1 in a high proportion of progenitor cells to study the effects of Wt1 
ablation on nephrogenesis.  
We found that Wt1 ablation in stromal progenitors (FOXD1+) did not seem to affect 
kidney development. The F-Wt1 mutant kidneys appeared normal phenotypically and 
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histologically. Cell tracking with a β-gal reporter showed that the stromal progenitor derived 
cells with Wt1 ablation could differentiate and persisted in the adult kidney. A previous study 
showed that FOXD1+ stromal progenitors gave rise to FLK1+ endothelial progenitors and 
contributed partially to the vasculature patterning of the kidney (Sims-Lucas et al., 2013). An 
in vitro culture study showed, at the periphery of embryonic kidney where the stromal 
progenitors reside, FLK1+ angioblast mesenchyme expressed Wt1 and Wt1-stimulated 
Vegfa signaling was essential to initially induce but not required to sustain the differentiation 
of the MM and the outgrowth and branching of the ureteric bud (Gao et al., 2005). These 
studies suggested that Wt1 in stromal progenitors could regulate the mesenchyme-ureteric 
bud interaction. However, our in vivo mouse model with Wt1 ablation in stromal progenitors 
did not show a defect in nephrogenesis. The different outcomes between our findings and 
the previous study of Wt1 in angioblasts could be due to the differences in using an in vivo 
genetic model in our study versus using the in vitro culture method employed in the previous 
study, or because we ablated Wt1 at a stage which has passed the time for the requirement 
of angioblast-mesenchyme for initial induction of nephrogenesis. 
When Wt1 was ablated in nephron progenitors (SIX2+), the nephrogenic zone (NZ), 
where the progenitors reside, was expanded with increased numbers of cells condensing 
and surrounding the ureteric buds. The cells in the expanded NZ were proliferative and 
expressed the nephron progenitor markers (CITED1 and PAX2), confirming their nephron 
progenitor identity. The mutant kidneys expressed significantly higher levels of the marker 
for intermediate mesenchyme, Osr1, than did the normal kidneys, suggesting that Wt1 
ablation may have reprogramed nephron progenitors to an OSR1+ cell state which is an 
earlier lineage than the nephron progenitor. This could explain the presence of ectopic 
skeletal elements in the human tumors with loss of Wt1 function mutations, which may result 
from the gained differentiation plasticity of the tumor cells. The gained multipotency and 
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long-term self-renewal caused the Wt1-ablated mutant cells to become partially transformed 
and be good candidates for transformation once another oncogenic event occurred.  
Furthermore, in the S-Wt1 mutant kidneys, nephrogenesis was blocked. The disrupted 
nephrogenesis phenotype appeared as early as at E15.5 in the mutant kidneys. The results 
with S-Wt1 mutant kidneys indicated that Wt1 ablation in the nephron progenitors prevented 
the cells from differentiating but sustained the undifferentiated state of the nephron 
progenitor. This result was consistent with the findings of previous studies. When Wt1 was 
ablated at E11.5 using a ubiquitous Cre, the metanephric mesenchyme did not condense 
and the MET process was blocked (Hu et al., 2010). Knock-down of Wt1 using siRNA in 
mouse embryonic kidney rudiment in vitro also showed abnormal cell proliferation and 
disrupted cell epithelial differentiation (Davies et al., 2004).  
Deletion of another Wilms tumor suppressor, Wtx, also presented a similar phenotype in 
neonatal kidneys (Moisan et al., 2011). Although Wtx-/- kidneys showed normal 
nephrogenesis, they had expanded pools of aggregates of SIX2+ cells and altered cell fate 
commitment and delayed differentiation in mesenchymal progenitor cells (Moisan et al., 
2011). The defects in cell fate determination were regulated by abnormal activation of β-
catenin signaling (Moisan et al., 2011). Interestingly, in our Wt1 ablated mutant kidneys, the 
expression of Axin2 (the effector of WNT/β-CATENIN signaling) was significantly higher than 
the normal kidneys, suggesting that β-catenin activation may also be involved in the defects 
in cell differentiation of nephron progenitors that were caused by Wt1 ablation. Wnt4 was 
identified as a Wt1 transcriptional target to promote the MET (Sim et al., 2002), but in our 
study Wnt4 was not differentially expressed between the S-Wt1 mutant kidneys and the 
normal kidneys. 
In addition, S-Wt1 mutant kidneys from 1 month and 2.5 months old mutant mice 
showed a thinner cortex and multiple fibrotic lesions. However, it was unknown whether 
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these fibrotic cells were derived from Wt1 ablated nephron progenitor or whether they were 
a secondary response to signaling caused by Wt1 ablated but phenotypically normal cells in 
the kidney. β-gal reporter tracking of Wt1 ablated cells showed that the cells in the fibrotic 
lesions did not express β-gal, suggesting that the lesional cells may not come from nephron 
progenitors, although this result could also have been caused by the scarcity of cytoplasm in 
the lesion cells which was insufficient to visualize β-gal staining. Lack of the expression of 
nephron progenitor markers SIX2, CITED1 and precursor epithelial marker K-CADHERIN in 
these cells suggested these cells were not persisting progenitor cells or abnormally 
differentiating epithelial cells. F4/80 staining showed that these cells were not infiltrating 
inflammatory cells. Ubiquitous deletion of Wt1 in adult mice also showed no systemic 
inflammatory response in the mutant although the mutant had acute multiple organ failure 
due to disturbed tissue homeostasis (Chau et al., 2011). In the adult S-Wt1 adult mice, the 
cells in the lesions were proliferative. VIMENTIN and COLLAGEN IV staining showed that 
these cells were mesenchymal and Masson’s Trichrome staining confirmed these cells were 
associate with fibrotic tissue. Increased COLLAGEN IV expression indicated TGFβ signaling 
may be involved. Further analysis of IHC and qPCR needs to be done to identify the 
dysregulated signaling pathway resulting in fibrosis formation.  
Our study of ablating Wt1 in nephron progenitors has shown that Wt1 promotes the 
nephron progenitors to differentiate and that loss of Wt1 sustains the long-term self-renewal 
capability and multipotency of the lineage-restricted nephron progenitors, making these cells 
good targets for cell transformation.  
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Conclusion and Significance 
In conclusion, we investigated the cell origin of Wilms tumor and the effects of genetic 
mutations on formation of different tumor types by using mouse genetic models. Our study 
has demonstrated that during kidney development the nephron progenitors can give rise to 
Wilms tumors with Wt1-Igf2 or β-catenin mutations but the stromal progenitors are not at risk 
of tumor development with these genetic alterations. With the nephron progenitor cell origin, 
Wt1-β-catS tumors and Wt1-Igf2 tumors had similar profiles in tumor latency and tumor 
frequency. However, the type of gene mutations affects the differentiation program of the 
transformed cells, thus resulting in different types of tumors. The Wt1-β-catS mutations 
resulted in epithelial differentiated Wilms tumors, whereas the Wt1-Igf2 alterations led to 
more mesenchymal Wilms tumors. Moreover, we characterized the effects of Wt1 ablation in 
the stromal and nephron progenitors on kidney development in order to understand the 
mechanisms by which Wt1 inactivation mutations predispose to WTs. Wt1 does not seem to 
be critical in stromal progenitors, but in nephron progenitors Wt1 is essential for the 
mesenchyme to epithelial transition and may regulate the dedifferentiation program of 
nephron progenitors. 
Wilms tumor is genetically and histologically heterogeneous. Understanding the impact 
of the differentiation status of tumor initiating cells on resulting tumor biology and the effects 
of gene mutations on the formation of different tumor types can provide significant insights 
into the mechanisms of the tumorigenic processes. Knowledge of the functions of Wt1 in 
renal progenitors will further help us to understand how Wt1 mutations transform the 
progenitors to tumor cells.  
Wilms tumor patients are sometimes treated with chemotherapy and radiation therapy, 
which can cause side effects and place them at risk for a secondary tumor later in life. 
Targeted therapies are needed to help reduce such side effects while providing effective 
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treatment. The mouse models of different types of Wilms tumors provide a useful tool for the 
identification of the biomarkers associated with different tumor types and tumor stages. With 
the development of new tumor biomarkers, we can detect tumors at an earlier stage and we 
also can stratify patients according to their biomarker profiles and apply specific treatment 
strategies to specific tumor subsets. Moreover, the mouse models can be used to identify 
druggable protein targets which are the key regulators in Wilms tumorigenesis and used to 
screen and test drugs for the best efficacy for treating tumors with minimum side effects. 
The preclinical models can be utilized for the development of improved therapy for the 
ultimate benefits of these young patients.  
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Future directions 
A complete understanding of the tumor initiation process is important in preventing tumor 
development. Fluorescent protein reporter and sensitive imaging techniques are great tools 
to track Wilms tumor initiating cells to monitor the early stages of tumor development and 
tumor progression. These methods can be used to detect the presence of Wilms tumor 
precursor lesions and monitor when and how the lesions progress to tumors. Our mouse 
models have shown that tumors arising from the same nephron progenitor origin are 
different in histology, gene expression profile and differentiation status due to the different 
genetic mutations induced. Therefore it is interesting to investigate how these genetic 
alterations affected the formation of different types of tumors. With the tool of the reporter 
tracking tumorigenic cells, the pathological process can be monitored by analyzing the 
reporter labeled cells with the examination of histology, co-staining with antibodies for 
differentiation markers and cancer signaling regulators. Not only can we study how the 
tumor cells differentiate, but we also can investigate how the tumor cells interact with the 
tumor microenvironment. Moreover, tumor precursor lesions or small tumors at an early 
stage can be isolated with FACS of the fluorescent protein labeled mutant cells in order to 
allow gene expression and protein expression analysis of these cells. To examine tumor cell 
aggressiveness and metastatic potential, the isolated tumor cells can be injected as 
xenografts to test transplanted tumor growth and metastatic ability. 
To understand the molecular mechanisms of the development of different types of 
mouse Wilms tumors, microarray of the tumors can be performed to characterize the global 
gene expression patterns between the types of mouse tumors. These data can be analyzed 
with Ingenuity Pathway Analysis (IPA) to determine genes and pathways that are 
significantly differentially expressed between the different types of tumors. The expression 
profiles of mouse models then can be compared to the expression data of human subsets 
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with cross-species analysis and clustering of the results can be performed to find out 
whether there is an association of the mouse WTs with the human subsets. Potentially, with 
this bioinformatics information, drug targets and the biomarkers differentiating these tumor 
types may be identified. Thus this will help to develop targeted therapies for patients and 
potentially avoid the long-term side effects from chemotherapy and radiation.  
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